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Preface
Zika was an arbovirus not considered relevant until the epidemics of 2007, where in the is‐
lands of the Pacific, Yap, Micronesia, and others, and later in the Americas in 2015–2016, it
created a significant public health threat. Zika is a flavivirus that has been especially impor‐
tant not just for the high number of cases but also for its related morbidity. In the case of
adult population, multiple neurological diseases are already associated and in pregnant
women because of its confirmed teratogenic capacity, leading to microcephaly as well as
other central nervous system (CNS) birth defects [1-5]. Many countries in Latin America
were significantly affected; in addition to Brazil, this was also the case of Colombia [6-10],
where congenital cases (congenital Zika syndrome (CZS)) as well as complicated and even
fatal cases were published during the epidemics and beyond [11-15]. However, many as‐
pects are still to be defined, including the impact of co-circulation and coinfection with other
arboviruses (e.g., dengue and Chikungunya), where antibody-dependent enhancement
(ADE) is also a cause of concern [16-20].
Keeping these issues in mind, this book includes different topics with regard to epidemiolo‐
gy, clinical manifestations, treatment, and prevention of a wide spectrum of manifestations
caused by Zika virus in humans, especially including not only the CZS but also entomologi‐
cal aspects. This book has been organized in two major sections: (1) “Clinical Aspects” and
(2) “Epidemiological and Entomological Aspects.” Section 1 includes topics related to clini‐
cal aspects, including particularly the microcephaly and the CZS as well as coinfections. Sec‐
tion 2 includes genetic, geoepidemiological, preventive, and entomological aspects.
Commissioning of this book by IntechOpen team has been related in part to my long commit‐
ment with vector-borne, zoonotic, and tropical diseases and being the co-chair of the Working
Group on Zoonoses of the International Society for Chemotherapy (WGZ-ISC), as well as in
Colombia at the Committee on Zoonoses, Tropical Medicine, and Travel Medicine of the Co‐
lombian Association of Infectious Diseases (Asociación Colombiana de Infectología (ACIN)),
and more and recently important, the chair of the Colombian Collaborative Network on Zika
(Red Colombiana de Colaboración en Zika) (RECOLZIKA), since January 2016.
I have been involved in vector-borne diseases (VBD) for the last two decades, including ma‐
laria, leishmaniasis, Chagas disease, as well as dengue and, since 2014, Chikungunya and
emerging arboviruses, such as Zika. After moving from Venezuela to Colombia in 2011, I
have been involved in the research of VBD in Risaralda, such as malaria and leishmaniasis
(still prevalent in the area), where we still keep working on these important tropical diseas‐
es. Part of all this is a clear reflection of the work impulse at the Research Group Infection
Public Health and Infection (classified as A1 by Colciencias) of the Faculty of Health Scien‐
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have been involved in the research of VBD in Risaralda, such as malaria and leishmaniasis
(still prevalent in the area), where we still keep working on these important tropical diseas‐
es. Part of all this is a clear reflection of the work impulse at the Research Group Infection
Public Health and Infection (classified as A1 by Colciencias) of the Faculty of Health Scien‐
ces of the Universidad Tecnológica de Pereira, directed by Dr. Guillermo Javier Lagos-Gri‐
sales, who is not just a partner, a colleague, and a friend but also an extreme believer in our
work in vector-borne and zoonotic diseases. But, I must also recognize the beginning of a
significant collaboration after a meeting in Cartagena in 2013, during the Colombian Con‐
gress of Infectious Diseases, with Dr. Wilmer Ernesto Villamil-Gómez, from Sincelejo, Sucre,
Colombia, also part of the former Committee of Zoonoses and Hemorrhagic Fevers of the
Colombian Association of Infectious Diseases (Asociación Colombiana de Infectología
(ACIN)) (now called the Committee of Zoonoses and Tropical Medicine), who became since
that year my most important collaborator on arboviruses, including Zika.
Following the same philosophy as we had on my six previous books with IntechOpen, Cur‐
rent Topics in Tropical Medicine [21], Current Topics in Public Health [22], Current Topics in Echi‐
nococcosis [23], Current Topics in Chikungunya [24], Current Topics in Malaria [25], and Current
Topics in Giardiasis [26], this book does not intend to be an exhaustive compilation, and this
first edition has included not just multiple different topics but also a wide geographical par‐
ticipation from many countries of different regions of the world. Its online availability
through the website of IntechOpen, as well as the possibility to upload the complete book or
its chapters in personal websites and institution repositories, allows it to reach a wide audi‐
ence in the globe. Continuing on the series of Current Topics books, we are editing Current
Topics in Tropical Emerging Diseases and Travel Medicine.
I would like to give a very especial thanks to IntechOpen, and particularly to Romina Rovan
(Publishing Process Manager), for the opportunity to edit this interesting and important
book, as well as for her constant support. 
I want to take the appropriate time and space, as I use to do, to dedicate this book to my
beloved family (Aurora, Alfonso José, Alejandro, and Andrea (neurologist)) and particularly
to Diana, who is more than a wife. After 6 years together, I am so clear she is everything to
me. She is the engine of my life. We have gone through difficult moments, partially related
to my work, but our love is beyond that. I also would like to acknowledge my friends and
my undergraduate and postgraduate students of Health Sciences in Colombia, Venezuela,
and around Latin America. I want to thank my colleagues at the Working Group on Zoono‐
ses, International Society for Chemotherapy, and the Committee on Zoonoses, Tropical
Medicine, and Travel Medicine (formerly a Committee on Zoonoses and Hemorrhagic Fe‐
vers) of the Colombian Association of Infectious Diseases (ACIN) and a large list of the
members of RECOLZIKA (http://blog.utp.edu.co/arodriguezm/zika/). Special thanks to my
friend and colleague Dr. Guillermo J. Lagos-Grisales, MD, MPH, and to the members of our
research group and incubator consisting of young and enthusiastic medical students and
some veterinary medical students as well as young medical doctors, who are pursuing sig‐
nificant improvements in the understanding of the epidemiology of zoonotic, vector-borne,
parasitic, and in general infectious diseases in our country with international projection.
Year 2017 has been highly productive for this recognized group, which now was classified
by the National Agency of Science, Colciencias, in the highest rank “A1,” which is position‐
ing as a leader in infectious disease epidemiology research in the Coffee Triangle region and
in the country.
Finally, I hope our readers enjoy this publication as much as I did reading the chapters of
Current Topics in Zika.
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1. Introduction
1.1. Overview and general aspects of Zika
Zika virus (ZIKV) is a mosquito-borne flavivirus discovered in rhesus monkeys in the Zika 
close to Kampala, Uganda in 1947, but it was not until February 2016 that the World Health 
Organization (WHO) declared Zika a public health emergency [1–5]. The introduction and 
spread of ZIKV throughout Latin America embodies a convergence of ecologic, social and 
environmental factors that foster the emergence of new infectious threats in susceptible popu-
lations. Although ZIKV infection is typically asymptomatic or causes a mild flu-like, birth 
defects indicate a wide clinical spectrum that includes severe manifestations that underlie 
global concern [4–7]. These, along with evidence of non-vector-borne transmission routes such 
as vertical transmission, blood transfusion and sexual contact [8–11], highlight the need for 
augmented research in the area [12]. Currently, research efforts have been increasingly focus-
ing on disease prevention through vaccine design and understanding of the role of antibody 
disease enhancement (ADE) on the immunopathogenesis of severe cases and fetal outcomes. 
New diagnostic tools are required in order to bypass cross reactivity with other flaviviruses 
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like dengue or yellow fever, and there is a gap for implementation research in order to develop 
effective strategies for vector control and awareness programs among people [10−18].
2. Epidemiology
It is difficult to exaggerate the medical importance and burden of vector-borne infectious 
diseases as a series of emerging and re-emerging arboviruses epidemics are propagated in 
recent decades in previously unexposed geographic areas in Latin America and the Caribbean 
[9]. ZIKV has caused epidemics during 2015–2017 in different countries of the Americas, with 
more than 50 countries/territories affected in this region, and 148 globally affected in any 
form (including imported cases). After Brazil, probably Colombia is the second most affected 
country in the region, with over 100,000 cases having been reported from this northern South 
American country, reflecting overall incidence rates above 150 cases/100,000 [18]. During the 
years 2015–2017, the circulation of ZIKV was confirmed in 560 municipalities and four dis-
tricts of Colombia. Suspected cases of ZIKV disease have been reported in 245 municipalities, 
adding a total of 809 municipalities with reported cases between confirmed and suspected 
cases. Thirty-five territorial entities of the departmental and district order have notified the 
surveillance system of ZIKV [19].
Although Colombia is not currently (November 2017) at epidemic status for ZIKV, it has 
become endemic with continued transmission. The main territories affected are those with 
previous circulation of dengue and chikungunya. In this sense, the departments (at the first 
administrative level) of Valle del Cauca, Santander, Tolima, Cundinamarca and Meta account 
with more than the 60% of the cases reported during 2017. On the other hand, 238 cases of 
symptomatic ZIKV infection had been documented in pregnant women (37 confirmed cases), 
and 20 cases charted in municipalities with no previously known ZIKV transmission. By terri-
torial entity of residence, the one that has reported the largest proportion of cases is Santander 
with 46 pregnant women in the northeastern region, border with Venezuela [19].
3. Clinical aspects
It is estimated that 80% of people infected by ZIKV are asymptomatic, but they can still 
develop complications that lead the patient to death or generate severe chronic conditions 
such as Guillain-Barré syndrome. Asymptomatic individuals may be important for sustain-
ing ZIKV transmission within a population despite being undiagnosed as a ZIKV case [6, 20].
Individuals with acute, symptomatic cases (25%) experience fever (elevation of axillary body tem-
perature greater than 37.2°C), nonpurulent conjunctivitis, headache, myalgia, arthralgia, asthenia, 
maculopapular rash (usually in extremities and trunk) (Figure 1), lower limb edema and less fre-
quently, retro-orbital pain, and gastrointestinal disturbance such as abdominal pain, nausea, and 
diarrhea. Notwithstanding, afebrile patients with rash should also be assessed for ZIKV infection 
[3, 11, 12]. These relatively mild symptoms last a few days (4–7 days), uncommonly result in 
hospitalization and are hardly distinguishable from other, better-known disease caused by other 
arboviruses [7, 16, 21]. Some neurological manifestations including  Guillain-Barré  syndrome, 
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acute myelitis, and meningoencephalitis are associated with detection of ZIKV in the cerebro-
spinal fluid [2, 16, 22]. Interestingly, this virus can cross the fetoplacental barrier to affect the 
fetus and cause microcephaly, microcephaly-related intellectual disabilities to neonates, ophthal-
mological alterations, loss hearing and epilepsy. Evidence has suggested that ZIKV could also 
invade cardiac cells, which could explain a described association between congenital heart dis-
ease in an infant born to a ZIKV-infected mother [13, 23, 24]. Differentiation on clinical grounds 
alone is often a very difficult task. The biological and clinical behaviors exhibit not only different 
characteristics but also great similarities; thus, ZIKV could be easily confused with other arbovi-
ruses. The clinical picture may be further complicated by coinfections with various combinations 
of arboviruses [9, 12, 18].
4. Diagnostics
The transmission of the diseases through mosquito bite is the most common scenario in ZIKV 
infection, which was described in 1966 in Malaysia. However, few cases of nonvector-borne 
infections have been reported, and the existence of ZIKV in the pharynx and saliva of infected 
patients represents a potential but unproven route of transmission. ZIKV also has been 
detected in semen, cervicovaginal fluid and urine, consistent with several well-documented 
cases of sexual transmission [3, 14, 16, 25].
The diagnosis of ZIKV infection is established through detection of ZIKV RNA by reverse 
transcription polymerase chain reaction (RT-PCR) typically performed on serum, plasma 
or urine within 2 weeks of symptom onset. ZIKV can also be diagnosed by serology (IgM 
Figure 1. Clinical aspects of patients with Zika virus infection (confirmed by PCR) (pictures took and provided with 
patient authorization, by co-author Jose Antonio Suarez, Instituto Gorgas, Panama): conjunctivitis, rash, arthralgia.
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4. Diagnostics
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infection, which was described in 1966 in Malaysia. However, few cases of nonvector-borne 
infections have been reported, and the existence of ZIKV in the pharynx and saliva of infected 
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antibodies). Serum RT-PCR is positive if done in the acute phase of the viremia, in blood on 
the first 3–7 days of the onset of illness, and for up to 10–14 days in urine. Enzyme-linked 
immunosorbent assay (ELISA) is used to detect IgM, but unfortunately, there are only a few 
laboratories able to perform an ELISA for ZIKV. Fewer laboratories still are able to perform 
neutralization assays, which may be more specific than ELISA, but require greater resources 
and biosafety containment. Although the specific antibodies against ZIKV in serum (IgM 
antibodies) are detectable after 4 days of symptom onset, its diagnostic value is limited due 
to cross-reactivity with other flaviviruses. Comparing relative titers of binding or neutraliz-
ing antibodies may be helpful in discriminating ZIKV from related flaviviruses like dengue 
in research settings, this is not yet standardized to aid in clinical diagnosis [16, 21].
The probable modes of perinatal transmission are transplacental or may occur during 
delivery. Concern has raised about the possibility of breastfeeding transmission. Prenatal 
fetal evaluation of pregnant women suspected or confirmed to have a ZIKV infection is 
done by regular fetal ultrasound examination, which can detect abnormalities as early as 
18–20 weeks of gestation. The main ultrasound findings associated with fetal ZIKV infection 
are microcephaly, intracranial calcifications, hydranencephaly, ventricular dilatation, brain 
atrophy, anhydramnios, hydrops fetalis, and intrauterine growth retardation. Amniotic fluid 
obtained by amniocentesis after 15 weeks of gestation can be tested for the presence of viral 
RNA by RT-PCR, but the sensitivity and specificity is unknown during gestation [13, 21, 26].
It is important in the differential diagnosis of dengue and chikungunya, among other condi-
tions such as malaria, leptospirosis, measles, and also to consider the possibility of coinfec-
tions, especially in endemic areas where all these pathogens can cocirculate simultaneously. 
During the symptomatic period of infection, various laboratory parameters provide informa-
tion on ZIKV infection. Various laboratory parameters such as leucopenia, thrombocytope-
nia, serum lactate dehydrogenase, gamma glutamyl transferase and elevated protein markers 
may be suggestive of ZIKV infection, but these findings are nonspecific [4, 13, 26]. Also, the 
virus can be detected in semen up to 81 days after infection.
5. Treatment
Currently, there is no ZIKV vaccine available, but the WHO has made ZIKV vaccine develop-
ment a top priority. Thus, more than 50 ZIKV vaccine candidates are now in various stages of 
research and development, mainly, in phase I/II clinical trials that include inactivated whole 
viruses, recombinant measles viral vector-based vaccines, DNA and mRNA vaccines, and a 
mosquito salivary peptide vaccine [17, 27].
The treatment for ZIKV infection is entirely supportive, no antiviral. No drugs have yet been 
approved for a specific ZIKV treatment, although numerous nucleoside analogs have some 
antiviral activities in cell cultures such as ribavirin, sofosbuvir or favipiravir. Acetaminophen 
is used to control fever and pain, avoiding aspirin or nonsteroidal anti-inflammatory drugs, 
because of their risk of hemorrhage (in case of DENV infection), and fluids are generously 
administered to prevent dehydration [24, 26, 28].
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6. Control and prevention
During the last few decades, Latin America has been threatened by an unprecedented explo-
sion of emerging arboviral outbreaks. These epidemics of emerging and re-emerging arbovi-
ruses are due to a number of factors such as climate change, levels of urbanization, increasing 
international travel, foreign trade, poor socioeconomic conditions, susceptible geographical 
areas (tropical and subtropical regions) among other factors. The presence of Aedes mosquitos 
enables ZIKV to invade new areas and poses a worldwide risk as there are no preventive 
approaches or vaccines for ZIKV [9, 12, 16, 26].
In countries where ZIKV epidemics are reported, cost-effectiveness studies may be important 
to determine the feasibility of systematic screening of blood components in donated samples. 
Unfortunately, at the moment, no specific data are available on the rate of reduction of blood-
borne transmission due to such practices. Because the prevalence of viremia in blood donations 
is high in endemic areas, mainly asymptomatic donors, donor selection professionals should 
carefully evaluate the appropriateness of the donation based on the patient’s background, like-
wise, follow up on donors with the aim of identifying the onset of symptoms [16, 26].
The most challenging aspect of ZIKV is preventing congenital infection. Recommendations 
to avoid mosquito exposure or avoid pregnancy altogether are not practical for most women 
living in ZIKV-endemic areas. Women who are or are planning to become pregnant are dis-
couraged from visiting areas of ZIKV transmission by travel restrictions issued by the US 
Center for Disease Control and other public health institutions. For preventing the sexual 
transmission of ZIKV for couples in which a man has traveled to or resides in an area with 
active ZIKV transmission, safe sexual practices for 6 months after the exposure regardless of 
the appearance of symptoms are recommended. What constitutes totally safe sexual practice 
is unclear, and some studies suggest that transmission of the small ZIKV (40 nm) may not be 
fully prevented by condoms [1, 2, 26, 29].
Much work remains before effective antiviral drugs and vaccines are available for ZIKV. For 
the time being, recognizing the importance of epidemiological control of emerging viral dis-
eases and taking preventive measures such as the increase in Aedes vector control and contain-
ment strategies guided by the scientific literature is a priority to achieve control of tropical 
viruses with epidemic potential [2, 3, 9]. In general, in countries with sporadic imported cases 
of ZIKV infection or in ZIKV-free countries, the only precaution that must be taken is to notify 
the cases. However, for epidemic areas, the main way to combat ZIKV is to cover skin by 
cloths, use mosquito repellents, reside in air-conditioned or screened rooms, and avoid being 
near water containers like stagnant water ponds, old automobile tire or plants containing 
water [16, 17, 26].
Finally, it is important to note that because only symptomatic individuals are diagnosed 
with ZIKV, robust epidemiologic data required for optimal control programs are lacking. 
Additionally, only a few reported cases have received laboratory confirmation; thus, condi-
tions such as dengue, chikungunya, malaria, leptospirosis, measles, among others may be 
incorrectly identified as ZIKV (or vice versa).
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Abstract
Zika virus is an arbovirus that is spreading at an alarming state in the American continents 
and now in Asian countries. The Aedes mosquitoes are the vectors for the spread of this 
virus beside other ways of transmission. Currently, there are no vaccines or drugs available 
for its treatment. The Zika virus–related microcephaly cases are reported in fetuses of preg-
nant women who got this viral infection. However, the exact mechanism of Zika virus and 
microcephaly is still not established. Here we review Zika virus epidemiology, its unusual 
relationship with microcephaly in fetuses and current scientific research progress on it.
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1. Introduction and background
Zika virus (ZIKV) of the family Flaviviridae was on the list of neglected diseases, and like all 
neglected diseases, it is now an epidemic causing microcephaly in new-born and Guillain-
Barré syndrome in adults [1]. The Aedes aegypti mosquitoes are the main vectors for it beside 
other reported species like Aedes hensilli [2]. Historically, it was identified back in 1947, and 
recently, Chang et al. have thoroughly discussed its full history [3] and several authors have 
reviewed the literature [4–9], but still there is a need for updated information. In the past 70 
years, different strains of Zika virus have been isolated from time to time in different parts of 
Africa [10–15]. It is generally believed that the current progress in human travel technology 
and its frequent use by people and the spread of Aedes due to its invasive nature cause the 
global spread of Zika virus [6]. Zika virus infection was also reported in a few returning trav-
elers in the Netherland and Switzerland, so its possible spread to the Europe is also difficult 
to avoid [16–18]. It was recently reported that another vector mosquito called Aedes albopictus 
has the capacity to spread Zika virus in North America and Europe [19].
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The threat of Zika virus to the United States population was not given importance initially, 
but several reports from Puerto Rico, Texas, and other parts alarm bells in the scientific com-
munity and a wake-up call to National Institute of Health [20, 21]. Zika virus is now on the 
door step of Asia with cases reported from Manila (Philippines), and parts of Singapore, 
Thailand, India, etc., which have favorable environmental conditions for Aedes mosquitos, 
and in the past, minor outbreaks were also recorded [14, 22–24]. This is an alarming situa-
tion and there is no preparation on the emergency basis. In the past, several cases of Zika 
virus were reported in Asian countries like Cambodia [25] and Senegal in Africa [26, 27], 
but it was not that widespread. Before 2007, few cases were reported at different places in 
different times, but it is suggested that increase in mosquito breeding and environmental 
changes due to human activities may cause mutation in the RNA genome of Zika virus and it 
becomes more adaptable to the mosquitos [28, 29]. In 2014–2015, Zika virus infection spread 
in South and Central America and Caribbean regions and is now spreading to other parts of 
the world [20, 30]. The spread of Zika virus in northeastern parts of Brazil occurred in the 
beginning of 2015 when it was observed that some patients had mild fever, rash, conjuncti-
vitis and arthralgia and their tests were negative for dengue virus [31]. Later on, the reverse 
transcription-polymerase chain reaction from the sera showed the presence of Zika virus and 
its classification showed that it belonged to the Asian group [31]. The human skin fibroblasts 
cells are permissive to Zika virus entry. The viral replication in infected cells causes activation 
of an antiviral innate immune response with the production of type I interferons [32].
2. Transmission
The common possible ways of spreading beside the mosquito bites and transplacental trans-
mission are blood transfusion, transplantation of organs, sexual activities, breastfeeding [33], 
respiratory along with sweat and tear droplets and animal bite [28, 34]. In North America 
and European countries, the spread through sexual contacts are more as these regions are 
not favorable for Aedes mosquitos [35]. In such areas, blood and semen donations should be 
properly checked for the presence of Zika virus, and further, people coming from affected 
areas should take care when they donate blood and semen in unaffected areas [36].
3. Relation between Zika virus and microcephaly
Microcephaly is one of the associated medical effects of Zika virus infection in mothers with 
their new born babies [36–40]. In the past, cases of Zika virus with microcephaly were not that 
common, but in Brazil, it was observed that the rate of microcephaly is twenty times more, 
which is quite alarming and new cases are still emerging [41]. Zika virus has the capacity to 
cross the placental barrier and infect the fetus [42, 43]. The infected mothers of these babies 
have rashes in the first and second trimesters [44]. Beside microcephaly, brain calcifications, 
cataracts and intraocular calcifications of eyes in fetuses are also reported [45]. In other cases, 
agyria, hydrocephalus and associated cortical displacement and mild focal inflammation are 
also present [46–48]. Similarly in another case in addition to the above-mentioned symptoms, 
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ultrasound of the infected fetus showed damaged lesions of posterior fossa and ascites along 
with subcutaneous edema [49]. Recent studies also suggested that the brain tissue and cells are 
favorable places for Zika virus growth as it targets the brain tissues in the neonate very easily 
[50, 51]. Zika virus decreases the viability and growth of neurospheres and brain organoids, and 
in that way, it targets the brain to cause microcephaly [52, 53]. Bullerdiek et al. hypothesized 
that the virus proteins affect the mitotic spindle proteins and their apparatus and this could be 
the possible way through which Zika virus causes teratogenic effects like microcephaly [54].
There are also ambiguities about the role of Zika virus and microcephaly, as in the past micro-
cephaly was not linked with Zika virus infection, and the cases of microcephaly were very low 
and it is possible that other factors may be involved in it [55, 56]. Evans et al. suggested that the 
insecticide pyriproxyfen that is used for the control of mosquito populations in drinking water is 
the possible agent for microcephaly in Brazil [57]. The insecticide pyriproxyfen has shown to act 
as juvenile hormone and has cross-reactivity with most of the fat soluble molecules like retinoic 
acid (a  metabolite of vitamin A) and a ligand for RXR receptor [57]. The RXR receptor is a type 
of nuclear receptor and this cross-reactivity of two agents results into abnormal activity of RXR 
receptors with the ultimate abnormality of microcephaly [57]. However, experiments on zebra 
fish models showed that pyriproxyfen did not cause any deformities in the central nervous sys-
tem [58]. To counter such ambiguities, different groups are studying the effect of Zika virus on 
mouse models, and in one of the recent reports, the researchers showed that when a mouse is 
infected with a Brazilian Zika virus strain, it causes intrauterine growth restriction and signs of 
microcephaly were also observed [59]. They also showed that Zika virus attacks the human corti-
cal progenitor cells and destroys them, and further the viral infection also damages the human 
brain organoids with a decrease in proliferative zones and damages the cortical layers [59]. In 
different brain and neural cells infected with Zika virus, it has been observed that the viruses halt 
the process of mitoses and damage the centrosome and the structural organization of the divid-
ing cell with ultimate result of cell death [60]. It has been observed that a single point mutation of 
serine to asparagine (S139 N) in the ZIKV polyprotein resulted in high virulence ability in human 
progenitor cells [61]. This mutation occurred before the 2013 French Polynesia and was main-
tained during the later spread of ZIKV in the Brazil and its neighbors [61]. ZIKV has the capacity 
to infect the placental barrier cells and thus damage the fetus [62]. ZIKV has the sole capacity to 
interact with anexelekto, meaning uncontrolled (AXL)  receptor, which is a tyrosine kinase recep-
tor on the placental barrier cells while other Flaviviridae viruses cannot link with these recep-
tors [62]. The other important arboviruses that damage the nervous system include the Japanese 
encephalitis virus (JEV) from the family Flaviviridae [63]. The vector for JEV is Culex mosquito 
species that feeds mostly on birds and livestock blood while humans are the accidental host of 
the virus [63, 64]. JEV causes birth defects and certain neurological complications [63]. A number 
of vaccines are available, but it is still endemic in South East Asian countries [63, 65]. Beside its 
effects on nervous system, Zika virus also damages the kidneys, eyes and genital organs [66–69].
4. Current scientific progress
For understanding the pathobiology and development of vaccines and drugs, it is important 
to sequence the genome and crystallize the important proteins of Zika virus. Recently, a Zika 
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virus strain named ZikaSPH2015 genome has been fully sequenced that contained all the struc-
tural and nonstructural proteins. This strain was isolated from a patient in São Paulo, Brazil 
[70]. In the past, a Zika virus strain from French Polynesia was also sequenced and the results 
showed its Asian background [71]. It is important to compare the genome of different strains 
and observe the differences in them for the possible mutations. Previous phylogenetic studies 
showed that there are basically two strains, one Asian and the other African, with some modi-
fications due to glycosylation of amino acid sequence [72]. Recently, Kostyuchenko et al. have 
resolved a 3.7 Å resolution structure of Zika virus through cryoelectron microscopy [1], while 
Sirohi et al. have resolved a 3.8 Å resolution structure of mature particles [73]. As compared to 
other flaviviruses, Zika virus is stable even at 40°C. They also showed that its envelope (E) pro-
tein is similar in structure and function to that of West Nile and Japanese encephalitis viruses 
and dengue virus [1].
The isolation, purification and crystallization of different Zika virus proteins are also in prog-
ress and they will be helpful in designing vaccines and chemotherapeutic agents (Figure 1) 
[74]. The nonstructural protein (NS1) crystal structure showed unique electrostatic properties 
at the host interaction site and it is possible in different modes of action as compared to other 
NS1 proteins of flaviviruses [75]. It was also observed that the NS1 codons are helping more 
in adaptation to humans, as in the past Zika virus was more restricted to the zoonotic cycle 
[76]. Tian et al. resolved the crystal structure of helicase of Zika virus and they observed that 
Figure 1. Sketch of the 11 kb genome of ZIKV and its important proteins. (A) The polyprotein and its cleavage products. 
(B) Topology of the polyprotein inside the membrane [85].
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structurally it is similar to that of dengue virus but there are some differences in the motor 
domain [77]. That is why, Zika helicase binds to RNA differently  and certain conformational 
changes can be seen in the motor domain [77]. Jain et al. resolved a 1.6 Å resolution structure 
of nonstructural (NS3) protein that acts as an RNA helicase of Zika virus, which was a French 
Polynesia strain [78]. This NS3 has similarity with that of dengue NS3 but there are some 
variations in its binding loops of ATP and RNA. This NS3 structure might be helpful in mak-
ing necessary drugs to control Zika virus [78]. Rossi et al. studied Zika virus in murine models 
and this study could be helpful in the development of vaccines and drugs [79]. Shan et al. 
made an infectious cDNA clone of Zika virus using the clinical isolated strain of Zika virus 
of Asian origin [80]. This cDNA clone can infect the brain cells in mice and it can also infect 
the Aedes mosquito; thus, it is a useful tool to study the virus transmission, related diseases 
and research suitable therapeutics [80]. Like dengue virus, model studies suggested that there 
are chances that it will spread throughout the world [81, 82] and it may be possible to spread 
along with other flaviviruses like dengue, West Nile virus, chikungunya and Stratford virus 
due to the common vector Aedes [83, 84].
5. Vaccine and drugs
Some scientific groups have suggested releasing the Wolbachia-harboring mosquitoes in 
the environment as competitors for Aedes mosquitos because they are resistant and they 
do not carry Zika virus; in this way, we can control the spread of Zika virus [86]. There 
is no vaccine or medicine available for the treatment of Zika virus, so it is important to 
be safe from mosquito bite and sexual contacts in Zika virus–affected places, which is the 
only solution [34, 87]. The health departments of USA are giving guidelines from time to 
time for prevention and control of Zika virus [88, 89]. Currently, different research insti-
tutes are working in developing a vaccine against this virus, but it will certainly take time 
in preparing it [90–93]. It has been observed that the polyphenol epigallocatechin 3-gal-
late (EGCG) inhibits the entry of Zika virus into the cell [94]. This polyphenol is present 
in green tea and is also part of many dietary supplements. Such observations were also 
recorded previously for other viruses, especially hepatitis C and herpes simplex, but how 
efficient this compound exactly is and its mechanism of action are still not clear [95–99]. 
Larocca et al. made DNA vaccines that express the premembrane and envelope protein 
of Zika and offer protection against the Brazilian virus challenge in murine models [100]. 
This initial vaccine development is a positive sign of a more effective vaccine development 
and its marketing in the near future for the control of Zika virus. It is also reported that 
those parts of Brazil where yellow fever vaccination was done have lower level of micro-
cephaly cases due to Zika virus [101]. Thus, there is a possibility that the yellow fever vac-
cine may be helpful for the treatment of Zika virus infection. An opposite case to this was 
reported where a male American traveler had yellow fever vaccination record but still he 
developed symptoms of Zika virus infection like rash, fever, extreme fatigue, back pain 
and conjunctivitis [102]. There are also suggestions to develop better mouse and other ani-
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mal models that can be used to study the pathogenesis and vaccine development of Zika 
virus; further, the already present neuroteratogenic problem–causing virus models can 
also be utilized for Zika virus infection [103–106]. Computational studies predicted that 
the antibodies are produced in humans during Zika virus and the infection causes an auto-
immune response that results in rash, microcephaly and other symptoms [107]. Therefore, 
remedy for such autoimmune proteins should also be considered for treatment during 
development of vaccines and drugs. On the drug and development side, it was noted that 
the 7-deaza-2′-C-methyladenosine (7DMA) has the potency to inhibit the replication of 
Zika virus in mice, and further trials should be performed to check its efficiency against 
different strains of Zika virus [108]. Eyer et al. tested a series of substituted nucleoside 
bases to inhibit the replication of Zika virus and they observed that the 2′-C-methylated 
nucleosides are promising drug candidates [109]. For research purposes, it has been sug-
gested that the famous adenosine analog NITD008 that has been used in the past against 
other viruses [110–112] also has the antiviral activity both in vitro and in vivo against Zika 
virus [113]. Now, the sequences and in some cases the crystal structure of different impor-
tant Zika virus proteins are available and they can be targeted through computational 
drug designing techniques [114–117]. Similarly, the already available data on the closely 
related viruses like dengue virus enzymes can be exploited for novel drug design [118]. In 
mouse model, it was noted that 25-hydroxycholesterol prevents the entry of virus particles 
inside the cell and is the first line of defense molecule [119]. One of the positive aspects of 
ZIKV is that it can be utilized for brain cancer treatment. It was observed that the ZIKV 
possesses oncolytic properties and it can destroy brain cancer cells called glioblastoma 
with high specificity [120].
6. Conclusions
The way Zika virus is spreading silently first in South America and now in Asian countries is 
quite alarming. If the spread continues and microcephaly cases increase, then a whole gen-
eration born might be a patient of microcephaly. Zika virus has already affected the tourism 
economy of different countries, and if this spread persists in Asia, then the loss will be too 
large. There is a need to figure out how exactly Zika virus causes microcephaly. The current 
research progress in terms of vaccine and drug development is at a snail pace and collabora-
tive efforts are required to control this viral disease. Further, the spread of Aedes mosquitoes 
is also alarming as they are the source of other viruses too, and controlling the vector means 
control on ZIKV, dengue and chikungunya.
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Abstract
“Outbreak” is a term referring to a virus or a parasite that is transmitted very aggres-
sively and therefore could potentially cause fatalities, as the recent Ebola and Zika epi-
demics did. Nevertheless, looking back through history, quite a few outbreaks have 
been reported, which turned out so deadly that essentially changed, molded and liter-
ally re-shaped the society as it is today. In the present chapter, differences and similari-
ties between the two most recent outbreaks have been studied, in order to pinpoint and 
design a trace model that will allow us to draw some conclusions for the connection of 
those two epidemics. Due to the high dimensionality of the problem, modern and state 
of the art geo-epidemiological methods have been used in an effort to provide the means 
necessary to establish the abovementioned model. It is only through geo-epidemiologi-
cal analysis that it is possible to analyze concurrently a multitude of variables, such as 
genetic, environmental, behavioral, socioeconomic and a series of related infection risk 
factors.
Keywords: genetics, evolution, epidemiology, Zika, Ebola
1. Introduction
The Flaviviridae is a diverse viral family of more than 100 known viral species, which has 
a worldwide distribution with several different viral members across the continents of our 
planet [1]. The first Flaviviridae virus outbreak was recorded in 1878 with the yellow fever 
virus at the city of Memphis, Tennessee, a hometown of 45,000–50,000 people that suddenly 
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became a ghost town [2]. At the same time, germ theory was still a state of the art concept. 
Researchers had no idea that the cause of yellow fever was a virus 1000 times smaller in size 
the human eye could detect, and they definitely had no idea that arthropod vectors were the 
carriers, and for this case mosquitoes in particular. Yellow fever virus was isolated for the first 
time in 1927, and it was not until 10 years later that an effective vaccine was developed against 
the fatal virus [3]. Due to the fact that Flaviviridae is a highly mutagenic family of viruses, 
in subsequent outbreaks, several new members have been identified and reported to share 
high similarity in structural conservation and molecular characteristics. Overall, the genus 
Flaviviridae comprises four main genera Hepacivirus, Pegivirus, Pestivirus and Flavivirus [4, 5].
The genus Hepacivirus is the smallest and contains the Hepatitis C Virus (HCV), one of the 
most fatal human pathogens in the Flaviviridae family [6, 7]. The genus Pegivirus was recently 
classified and includes virus species that infect mammals [4, 8]. The genus Pestivirus has not 
been classified as a zoonotic disease yet and contains the bovine viral diarrhea virus (BVD) 
and the classical swine fever virus (CFSV) [4, 9]. Nevertheless their impact on livestock is 
strongly connected with the economic and social well-being of many countries. Last but not 
least the genus Flavivirus is the largest one and contains 70 identified human and animal 
viruses [4] including Dengue virus (DENV), West Nile virus (WNV), Japanese encephalitis 
virus (JEV), Tick-borne encephalitis virus (TBEV), Yellow fever virus (YFV) and Zika virus 
(ZIKV) the last of which recently led to the World Health Organization (WHO) in order to 
declare a global public-health emergency.
Among other common characteristics, the Flaviviridae family viruses spread quickly and eas-
ily in a tropical environment and attribute that the researchers are now re-examining the cur-
rent Zika virus outbreak [10, 11]. In fact, this is down to the way viruses pass from one species 
to another. The viruses within this family fall within significant medical concern as variety of 
diseases inflict to both humans and animals. The majority of these viruses spread by arthro-
pod vectors such as ticks and mosquitoes and in many cases they can also be transmitted from 
animals to humans. Flaviviridae family viruses can survive for long periods in their hosts by 
replicating without damaging the host cell. Generally, humans are infected with these viruses 
by direct contact with infected blood. In America, people have been mostly infected with Zika 
virus through the bites of the Aedes aegypti mosquito [12].
The ability of the Flaviviridae family viruses to spread so rapidly is also due to the structure 
of its viral genome [4, 13]. The Flaviviridae are a family of positive, single-stranded enveloped 
RNA viruses. Their genetic material in the form of ssRNA contains all the information needed 
in order to make copies and it also mutates more easily [14]. Mistakes in replication can hap-
pen in both DNA and RNA, but RNA has fewer systems in place to proofread and correct 
mutations that may naturally arise [15]. In fact the RNA viruses do not have these correcting 
mechanisms at all, so the mutations remain and get passed to the next generation [14]. RNA 
replication has an error rate roughly 10,000 times higher than that of DNA, which means that 
Flaviviridae family viruses evolve much quicker.
Flaviviridae family genera present similarities in the organization of its genetic material, the esti-
mate life cycle, replication and morphology of the viral particles [5]. Virions of Flaviviridae fam-
ily viruses are spherical almost 40–60 nm in diameter. Each virion consists of a lipid envelope 
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which is composed of two or three virus-encoded membrane proteins, a membrane and a small 
capsid. The genetic material is located within the capsid. The genome includes a single-stranded 
positive sense RNA molecule of approximately 9.5–12.5 kb. It contains a long open reading 
frame (ORF) which is found between untranslated regions (UTRs) at 5′ and 3′ ends. All the fam-
ily members lack 3′ terminal polyadenylated tail. The whole genome is translated into a poly-
protein, which is processed post-translationally by host and viral proteases. This polyprotein 
consists of minimum 10 different products, depending on the classification of the virus that can 
be divided based on structural and non-structural (NS) proteins [7].
2. General epidemiology
Despite the fact that the Zika virus epidemic in the Americas and the Caribbean is showing 
signs of a significant slow-down, Zika virus transmission is continued worldwide. To date, 
148 areas worldwide related with Zika virus from which 61 areas worldwide have confirmed 
the transmission of Zika virus disease, 18 areas have evidence of Zika virus circulation and 
69 have the potential for Zika virus future transmission [16, 17]. Moreover five countries have 
reported sexually transmitted Zika cases [18, 19]. There are critical knowledge gaps around 
Zika virus and a lack of historical reports on its vectors, transmission patterns and geographi-
cal distribution. Regardless these challenges, there is a need to better understand the epi-
demiology of Zika virus transmission in a given area, at a given time in order to allow an 
assessment of the possibility of Zika virus infection for a number of populations, and to adapt 
public health recommendations for residents and travelers [17].
The first isolation of Zika virus was detected in 1948 from the mosquito species Aedes 
africanus [20, 21]. Since then, there have been several new cases of Zika virus vectors reported 
to literature. Collectively, the most frequent mosquito vector is the genus Aedes including, 
A. aegypti, Aedes furcifer, Aedes luteocephalus, Aedes vitattus and Aedes apicoargenteus [22–24]. 
The main vector of the Zika virus in South and South-East Asia is considered to be the genus 
A. aegypti of mosquitoes, which also play a major role as the major transmission vector for 
Dengue virus, Yellow fever virus, Chikungunya virus and many other mosquito-borne flavivi-
ruses [25]. Based on reports during the two major outbreaks in the Pacific Islands, new poten-
tial vectors of Zika virus could be Aedes hensilli and Aedes polynesiensis mosquitoes [26, 27]. 
Moreover, recently another member of mosquitoes within the Aedes genus was found to be 
infected, the Aedes albopictu [12, 28]. Zika virus replicates in mosquitoes within 7–10 days and 
afterwards spreads with high levels of transmission through the salivary glands. However, 
the superiority of either vector over others in its capacity to optimally transmit Zika virus is 
yet to be investigated. Despite the Zika virus reservoir is unclear, some researcher believe that 
Zika virus might be maintained in nature by a sylvatic cycle involving non-human primates, 
or in a broad members of Aedes mosquito’s species [23, 24]. Zika virus transmission in urban 
areas takes place by the anthropophilic mosquitoes A. aegypti and A. albopictus, from which 
the A. albopictus is particularly worrisome from the A. aegypti because of its daily feeding and 
their custom to bite several hosts during the development cycle of their eggs which makes 
them very effective as a transmission vectors [21, 29, 30]. Nevertheless, serological studies 
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ily members lack 3′ terminal polyadenylated tail. The whole genome is translated into a poly-
protein, which is processed post-translationally by host and viral proteases. This polyprotein 
consists of minimum 10 different products, depending on the classification of the virus that can 
be divided based on structural and non-structural (NS) proteins [7].
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The first isolation of Zika virus was detected in 1948 from the mosquito species Aedes 
africanus [20, 21]. Since then, there have been several new cases of Zika virus vectors reported 
to literature. Collectively, the most frequent mosquito vector is the genus Aedes including, 
A. aegypti, Aedes furcifer, Aedes luteocephalus, Aedes vitattus and Aedes apicoargenteus [22–24]. 
The main vector of the Zika virus in South and South-East Asia is considered to be the genus 
A. aegypti of mosquitoes, which also play a major role as the major transmission vector for 
Dengue virus, Yellow fever virus, Chikungunya virus and many other mosquito-borne flavivi-
ruses [25]. Based on reports during the two major outbreaks in the Pacific Islands, new poten-
tial vectors of Zika virus could be Aedes hensilli and Aedes polynesiensis mosquitoes [26, 27]. 
Moreover, recently another member of mosquitoes within the Aedes genus was found to be 
infected, the Aedes albopictu [12, 28]. Zika virus replicates in mosquitoes within 7–10 days and 
afterwards spreads with high levels of transmission through the salivary glands. However, 
the superiority of either vector over others in its capacity to optimally transmit Zika virus is 
yet to be investigated. Despite the Zika virus reservoir is unclear, some researcher believe that 
Zika virus might be maintained in nature by a sylvatic cycle involving non-human primates, 
or in a broad members of Aedes mosquito’s species [23, 24]. Zika virus transmission in urban 
areas takes place by the anthropophilic mosquitoes A. aegypti and A. albopictus, from which 
the A. albopictus is particularly worrisome from the A. aegypti because of its daily feeding and 
their custom to bite several hosts during the development cycle of their eggs which makes 
them very effective as a transmission vectors [21, 29, 30]. Nevertheless, serological studies 
Genetic and Geo-Epidemiological Analysis of the Zika Virus Pandemic; Learning Lessons…
http://dx.doi.org/10.5772/intechopen.71505
35
have established the presence of particular antiviral antibodies in several mammals including 
elephants, felines and rodents, which confirm that other reservoirs may be involved in the 
transmission cycle of the Zika virus [21, 31]. Therefore, there is an urgent need to identify vec-
tors and possible vectors in vulnerable area in order to control Zika virus outbreaks.
3. Genetic and geo-epidemiological analysis of the Zika virus
Zika virus has been around since the first human case was diagnosed in 1952 [20]. It only 
caused sporadic human infections until the first humongous outbreak on the Micronesian 
island of Yap in 2007 [32]. Even then, the symptoms were reported to share many common 
characteristics with a mild flu symptoms including fever, rash, headaches and joint and muscle 
pain. However, during the Zika virus outbreak in Tahiti in 2013 and 2014, a small number of 
people began to show unusual symptoms that resembled another syndrome called “Guillain-
Barré,” a condition that causes the immune system to attack a person’s nerves, resulting in 
muscle weakness, tingling and even paralysis [33]. Furthermore, pregnant women infected 
with Zika virus have also given birth to babies with microcephaly, or smaller than normal 
heads [34]. It is possible that these new symptoms could be a result of the Zika virus evolu-
tion [35]. Zika virus was relatively infrequent and it did not cause a lot of concern, but when 
new cases were identified with greater frequency and people started to see babies born with 
microcephaly and nervous system disorders, the public health importance of this virus had 
to change completely [36].
The sudden appearance and the rapid global spread of the Zika virus have caused confusion 
regarding the meaning of the term “pandemic” [37]. There is also confusion in the recognition 
of pandemics when they occur. Some believe that the explosive contagiousness is sufficient 
to classify a disease as a pandemic. Another opinion claims that the severity of the infection 
and mortality must be considered. A pandemic is an epidemic of infectious disease that has 
spread throughout human population across a large region such as multiple continents or 
even worldwide [38]. The pandemic is not related to the endemic, which is a disease that 
can be controlled as far as transmissibility is concerned. On the other hand, the pandemic is 
characterized as a lethal threat to humans, since mortality rates may overcome these wars and 
accidents. The main feature of the pandemic is that it is communicable.
A look back in history reveals that pandemics are so expansive and deadly that they essen-
tially changed the course of history such as the Black Death or as well known as “Bubonic 
Plague” in 1339–1351, which affects both Europe and Asia [39]. Painful, egg-sized swellings 
on the body signaled the infected had only a week to live [40]. Being close to a sick person was 
enough to get infected. The total number of worldwide deaths is estimated at 75 million peo-
ple and even today the WHO reports 1000–3000 cases of plague every year [41]. Furthermore, 
Cholera boomed during 1817–1823 in Asia, Middle East and Africa. The cholera bacterium 
lurks in contaminated water and infects the small intestine, causing severe diarrhea. About 
40% of victims die within hours, due to dehydration. Cholera has killed at least 10 million 
people. An estimated 2.86 million cholera cases occur annually in endemic countries. Among 
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these cases, there are an estimated 95,000 deaths [42]. Nowadays, HIV/AIDS is still expanded 
worldwide since 1970, despite the fact that it is originated in central Africa [43, 44]. HIV virus 
viral genome was identified in the early 1980s, after an epidemic expand among homosexual 
men in western countries. HIV is transmitted through bodily fluids and blood, and destroys 
the immune system [45]. HIV infected people with zero immune response are easier to die of 
other diseases such as cancer or pneumonia, or from simple infections. Since there is no cure, 
anti-retroviral drugs are granted to the patients to prevent the virus from spreading and kill-
ing more immune cells. HIV and generally AIDS have killed more than half a million North 
Americans [46]. In Southern Africa, it is estimated that 25 million have lost their lives, with 35 
million more still infected, including many children born with the virus [47].
The World Health Organization (WHO) has produced a six-stage (phasing) classification that 
describes the process by which a novel influenza virus moves from the first few infections in 
humans through a pandemic [48]. The stages do not relate to how sick the person gets or how 
many people are infected by the virus. Instead, they relate to where it is located and how it 
is spread from one area to another. Firstly, viruses circulate within animals only. No human 
infection has resulted from the animal virus. Secondly, if an animal virus infects humans, it 
means that this virus has mutated, so there is a basic level of pandemic threat. Thirdly, small 
groups of people in a region are infected by the virus. It is possible to transmit the virus out-
side the boundaries of the community if others outside that community come into contact 
with those humans who are infected. The next phase is when the outbreaks of the virus are 
increasing dramatically in many communities in a short period of time. A stage before the 
pandemic is when the transmission of the virus from human to human has been recorded in 
at least two countries. Finally, the pandemic phase means a global pandemic is underway. 
Illness is widespread and governments and worldwide organizations are actively working to 
curtail the spread of the disease, and to help the population deal with it, by using preventive 
measures [49].
Due to the nature of pandemics, we will never be fully protected despite any development in 
antivirals and viral medicine [50]. The following categories are the most ominous: Viral hem-
orrhagic fevers, including Ebola and Marburg Virus, have the potential to turn into pandem-
ics. Influenza—the recent discovery of the H5N1 (Avian Flu) is an example of this. The strain 
was spotted in Vietnam in 2004; the ability of the virus to potentially combine with human 
flu viruses is a concern to scientists. Ebola—the largest Ebola epidemic the world has ever 
seen is still ongoing. Huge efforts have been made in order to prevent it from turning into a 
pandemic. Viral diseases occupy a dominant position in pandemics. The majority of deaths 
worldwide caused by viral pandemics, the mortality of diseases that belong to Flaviviridae 
family are shown in Table 1. A major problem is the immediate and prompt response for pro-
tection before a disease evolves into a pandemic. The progress of science in drug discovery is 
rapid, scientists replace the traditional methods of in vivo/in vitro trial error testing and focus 
more on techniques of rational drug design based on the structure which is efficient, fast and 
of lower cost [51].
To date there is neither a drug nor a specific vaccination available against Zika virus, Ebola 
or HIV virus. Thus there is a great need for the development of novel antiviral strategies. 
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Barré,” a condition that causes the immune system to attack a person’s nerves, resulting in 
muscle weakness, tingling and even paralysis [33]. Furthermore, pregnant women infected 
with Zika virus have also given birth to babies with microcephaly, or smaller than normal 
heads [34]. It is possible that these new symptoms could be a result of the Zika virus evolu-
tion [35]. Zika virus was relatively infrequent and it did not cause a lot of concern, but when 
new cases were identified with greater frequency and people started to see babies born with 
microcephaly and nervous system disorders, the public health importance of this virus had 
to change completely [36].
The sudden appearance and the rapid global spread of the Zika virus have caused confusion 
regarding the meaning of the term “pandemic” [37]. There is also confusion in the recognition 
of pandemics when they occur. Some believe that the explosive contagiousness is sufficient 
to classify a disease as a pandemic. Another opinion claims that the severity of the infection 
and mortality must be considered. A pandemic is an epidemic of infectious disease that has 
spread throughout human population across a large region such as multiple continents or 
even worldwide [38]. The pandemic is not related to the endemic, which is a disease that 
can be controlled as far as transmissibility is concerned. On the other hand, the pandemic is 
characterized as a lethal threat to humans, since mortality rates may overcome these wars and 
accidents. The main feature of the pandemic is that it is communicable.
A look back in history reveals that pandemics are so expansive and deadly that they essen-
tially changed the course of history such as the Black Death or as well known as “Bubonic 
Plague” in 1339–1351, which affects both Europe and Asia [39]. Painful, egg-sized swellings 
on the body signaled the infected had only a week to live [40]. Being close to a sick person was 
enough to get infected. The total number of worldwide deaths is estimated at 75 million peo-
ple and even today the WHO reports 1000–3000 cases of plague every year [41]. Furthermore, 
Cholera boomed during 1817–1823 in Asia, Middle East and Africa. The cholera bacterium 
lurks in contaminated water and infects the small intestine, causing severe diarrhea. About 
40% of victims die within hours, due to dehydration. Cholera has killed at least 10 million 
people. An estimated 2.86 million cholera cases occur annually in endemic countries. Among 
Current Topics in Zika36
these cases, there are an estimated 95,000 deaths [42]. Nowadays, HIV/AIDS is still expanded 
worldwide since 1970, despite the fact that it is originated in central Africa [43, 44]. HIV virus 
viral genome was identified in the early 1980s, after an epidemic expand among homosexual 
men in western countries. HIV is transmitted through bodily fluids and blood, and destroys 
the immune system [45]. HIV infected people with zero immune response are easier to die of 
other diseases such as cancer or pneumonia, or from simple infections. Since there is no cure, 
anti-retroviral drugs are granted to the patients to prevent the virus from spreading and kill-
ing more immune cells. HIV and generally AIDS have killed more than half a million North 
Americans [46]. In Southern Africa, it is estimated that 25 million have lost their lives, with 35 
million more still infected, including many children born with the virus [47].
The World Health Organization (WHO) has produced a six-stage (phasing) classification that 
describes the process by which a novel influenza virus moves from the first few infections in 
humans through a pandemic [48]. The stages do not relate to how sick the person gets or how 
many people are infected by the virus. Instead, they relate to where it is located and how it 
is spread from one area to another. Firstly, viruses circulate within animals only. No human 
infection has resulted from the animal virus. Secondly, if an animal virus infects humans, it 
means that this virus has mutated, so there is a basic level of pandemic threat. Thirdly, small 
groups of people in a region are infected by the virus. It is possible to transmit the virus out-
side the boundaries of the community if others outside that community come into contact 
with those humans who are infected. The next phase is when the outbreaks of the virus are 
increasing dramatically in many communities in a short period of time. A stage before the 
pandemic is when the transmission of the virus from human to human has been recorded in 
at least two countries. Finally, the pandemic phase means a global pandemic is underway. 
Illness is widespread and governments and worldwide organizations are actively working to 
curtail the spread of the disease, and to help the population deal with it, by using preventive 
measures [49].
Due to the nature of pandemics, we will never be fully protected despite any development in 
antivirals and viral medicine [50]. The following categories are the most ominous: Viral hem-
orrhagic fevers, including Ebola and Marburg Virus, have the potential to turn into pandem-
ics. Influenza—the recent discovery of the H5N1 (Avian Flu) is an example of this. The strain 
was spotted in Vietnam in 2004; the ability of the virus to potentially combine with human 
flu viruses is a concern to scientists. Ebola—the largest Ebola epidemic the world has ever 
seen is still ongoing. Huge efforts have been made in order to prevent it from turning into a 
pandemic. Viral diseases occupy a dominant position in pandemics. The majority of deaths 
worldwide caused by viral pandemics, the mortality of diseases that belong to Flaviviridae 
family are shown in Table 1. A major problem is the immediate and prompt response for pro-
tection before a disease evolves into a pandemic. The progress of science in drug discovery is 
rapid, scientists replace the traditional methods of in vivo/in vitro trial error testing and focus 
more on techniques of rational drug design based on the structure which is efficient, fast and 
of lower cost [51].
To date there is neither a drug nor a specific vaccination available against Zika virus, Ebola 
or HIV virus. Thus there is a great need for the development of novel antiviral strategies. 
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Viruses have a relatively simple structure. They contain nucleic acids in a capsid. The mecha-
nism used for their transmission is based on the host cell. In the end, the host cell is destroyed 
after the creation of multiple copies of the virus. An antiviral strategy for Flaviviridae family 
is to identify which proteins/enzymes are involved in viral replication. Important enzymes 
are the viral helicase and viral polymerases, NS3 and NS5, respectively [52]. The knowledge 
that the helicase plays a key role in the translation of Zika virus leads to the establishment 
and the design of homologous helicase models in order to be used for the rational design of 
an anti-Zika pharmacophore [53]. Also it has been shown that IFN, ribavirin, 6-azauridine 
and glycyrrhizin have the ability to inhibit infection of VERO cells induced with IFN to be 
more effective [54]. Moreover, the combination of IFN and ribavirin may be more effective in 
the Flavivirus genus. Researchers have shown that propoxy derivatives are good candidates 
for drugs against HCV [55]. Anti-malaria hydroxychloroquine indicated inhibition of dengue 
virus infection and has been safely used during pregnancy as well as amodiaquine and tetra-
cyclines [56].
Ebola virus disease (EVD) is a non-segmented, negative-sense, single-stranded RNA virus that 
resembles rhabdoviruses and paramyxoviruses in its genome organization and replication 
mechanisms. It is a member of the family Filoviridae, based upon their filamentous structure. 
The genus Ebola virus is divided into five species (Zaire, Sudan, Ivory Coast, Bundibugyo 
and Reston). Among them, the first four cause disease in humans. The disease has a high risk 
of death, killing between 25 and 90% of those infected, with an average of about 50% [57]. 
The disease was first identified in 1976 in two simultaneous outbreaks, one in Nzara and the 
other in Yambuku, a village near the Ebola River from which the disease took its name. The 
old virus differs from today by 3%. Ebola outbreaks frequently make their appearance in sub-
Saharan Africa. So far the greatest epidemic ever recorded was in western Africa (December 
2013–January 2016) with 11,315 confirmed deaths. Symptoms of Ebola typically include fever, 
Virus Case fatality rate (CFR) Diagnosed (per year) Deaths (per year)
Yellow Fever (YFV) 7.5% 200.000 30.000
Dengue Fever (DENV) 40–50% (without treatment)
1–5% (with treatment)
50–528 million 20.000
Japanese encephalitis virus (JEV) 0.3–60% 70.000 20.400
Tick-borne encephalitis virus (TBE) 20–40% far Easter
2–3% E.U, U.S.A
10.000–15.000 1000
Hepatitis C virus (HCV) 9% 3–4 million 350.000
West Nile virus (WNV) 3–15% 3.000 100
Zika virus (ZIK) — 1,5 million 18 (+71*)
*cases of deaths with microcephaly and/or central nervous system (CNS) 
malformation in newborns.
Table 1. Case fatality rate (CFR) of viruses in Flaviviridae family. Microcephaly and other fetal malformations potentially 
associated with Zika virus infection or suggestive of congenital infection, have been reported in seven countries or 
territories. Particularly, from October 2015 until January 2016, 4783 cases of microcephaly have been reported in Brazil. 
On 29 April the first American died of complications related to the Zika virus, health officials of CDC reported.
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severe headache, muscle pain, weakness and sore throat. Late-stage symptoms of Ebola virus 
may include vomiting, diarrhea, redness in the eyes, swelling of the genitals, internal and 
external bleeding. Typically, symptoms appear 8–10 days after exposure to the virus, but the 
incubation period can span from 2 to 21 days. Recovery may begin between 7 and 14 days 
after first symptoms. Death, if it occurs, follows typically 6–16 days from first symptoms and 
is often due to low blood pressure from fluid loss [58].
Ebola virus is transmitted from human to human by close contact with infected patients and 
virus-containing body fluids. Specifically, it spreads through direct contact with blood or 
body fluids (including but not limited to feces, saliva, sweat, urine, vomit and semen) of a 
person who is sick with or has died from Ebola [59]. Ebola can also be spread through needle 
sticks and contact with objects (like needles and syringes) that have been contaminated with 
the virus. According to WHO, you can also contract the virus by handling a sick or dead wild 
animal that has been infected with it. In the countries of West Africa, transmission through 
infected animals has been observed, usually infecting bats or wild animals as prey. The Ebola 
virus is also a sexually transmitted disease, transmitted by semen (oral, vaginal and anal sex) 
[60]. High-risk groups, except the population of sub-Saharan Africa are people surrounded 
by patients either in the family or in the professional environment. Scientists observing the 
virus have not seen any evidence to suggest that the Ebola virus may be mutating to become 
more contagious.
Ebola is difficult to be diagnosed when a person is first infected because the early symptoms, 
such as fever, are also symptoms of other diseases. The main question doctors consider is 
whether the person has been in one of the countries in West Africa within the last 21 days, 
then tests of blood and tissues can diagnose Ebola. Laboratory diagnosis of Ebola is achieved 
in two ways: detection of infectious particles (or particle components) in affected individu-
als and measurement of specific immune responses to Ebola virus [61]. To date, no FDA-
approved vaccine or medication is available against Ebola virus. Albeit, when some basic 
interventions are used early, they can improve the chances of survival. The basic interventions 
used are providing intravenous fluids (IV) and balancing electrolytes (body salts), maintain-
ing oxygen status and blood pressure and treating other infections if they occur, medications 
to treat shock and pain medications.
Since no therapy has been approved, an important issue that occurs is prevention. Preventive 
methods are vital. WHO and other global health organizations have suggested several types 
of protection, some of them are wash your hands with soap and water or an alcohol-based 
hand sanitizer and avoid contact with blood and body fluids, isolate the patient, wear protec-
tive clothing, dispose of needles and syringes safely, use safe burial practices and avoid facili-
ties in West Africa where Ebola patients are being treated.
To date, the largest outbreak of the Ebola virus was in West Africa. In March 2014, Guinea, 
Liberia and Sierra Leone were the countries where the major outbreak of Ebola appeared. 
In early October of the same year, the first transmission of the virus to occur outside Africa 
was reported, later other patients were identified in Europe and America. The numbers show 
the extent of the problem. In the period 2013–2015 in Liberia, Sierra Leone, Guinea, Nigeria, 
Mali, United States, Senegal, Spain, United Kingdom and Italy, there were 11,315 deaths with 
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and Reston). Among them, the first four cause disease in humans. The disease has a high risk 
of death, killing between 25 and 90% of those infected, with an average of about 50% [57]. 
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other in Yambuku, a village near the Ebola River from which the disease took its name. The 
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Table 1. Case fatality rate (CFR) of viruses in Flaviviridae family. Microcephaly and other fetal malformations potentially 
associated with Zika virus infection or suggestive of congenital infection, have been reported in seven countries or 
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after first symptoms. Death, if it occurs, follows typically 6–16 days from first symptoms and 
is often due to low blood pressure from fluid loss [58].
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virus-containing body fluids. Specifically, it spreads through direct contact with blood or 
body fluids (including but not limited to feces, saliva, sweat, urine, vomit and semen) of a 
person who is sick with or has died from Ebola [59]. Ebola can also be spread through needle 
sticks and contact with objects (like needles and syringes) that have been contaminated with 
the virus. According to WHO, you can also contract the virus by handling a sick or dead wild 
animal that has been infected with it. In the countries of West Africa, transmission through 
infected animals has been observed, usually infecting bats or wild animals as prey. The Ebola 
virus is also a sexually transmitted disease, transmitted by semen (oral, vaginal and anal sex) 
[60]. High-risk groups, except the population of sub-Saharan Africa are people surrounded 
by patients either in the family or in the professional environment. Scientists observing the 
virus have not seen any evidence to suggest that the Ebola virus may be mutating to become 
more contagious.
Ebola is difficult to be diagnosed when a person is first infected because the early symptoms, 
such as fever, are also symptoms of other diseases. The main question doctors consider is 
whether the person has been in one of the countries in West Africa within the last 21 days, 
then tests of blood and tissues can diagnose Ebola. Laboratory diagnosis of Ebola is achieved 
in two ways: detection of infectious particles (or particle components) in affected individu-
als and measurement of specific immune responses to Ebola virus [61]. To date, no FDA-
approved vaccine or medication is available against Ebola virus. Albeit, when some basic 
interventions are used early, they can improve the chances of survival. The basic interventions 
used are providing intravenous fluids (IV) and balancing electrolytes (body salts), maintain-
ing oxygen status and blood pressure and treating other infections if they occur, medications 
to treat shock and pain medications.
Since no therapy has been approved, an important issue that occurs is prevention. Preventive 
methods are vital. WHO and other global health organizations have suggested several types 
of protection, some of them are wash your hands with soap and water or an alcohol-based 
hand sanitizer and avoid contact with blood and body fluids, isolate the patient, wear protec-
tive clothing, dispose of needles and syringes safely, use safe burial practices and avoid facili-
ties in West Africa where Ebola patients are being treated.
To date, the largest outbreak of the Ebola virus was in West Africa. In March 2014, Guinea, 
Liberia and Sierra Leone were the countries where the major outbreak of Ebola appeared. 
In early October of the same year, the first transmission of the virus to occur outside Africa 
was reported, later other patients were identified in Europe and America. The numbers show 
the extent of the problem. In the period 2013–2015 in Liberia, Sierra Leone, Guinea, Nigeria, 
Mali, United States, Senegal, Spain, United Kingdom and Italy, there were 11,315 deaths with 
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case fatality rate of up to70–71%. The United National health agency in December 29, 2015 
declared the end of the Ebola virus transmission in Guinea, Liberia and Sierra Leone, where 
the epidemic began killing 13,000 people [62].
Zika virus was originally isolated in 1947 from the blood of a Rhesus monkey for yellow fever 
research conducted in the Zika forest, Uganda, from which the disease took its name. Then 
the virus was recovered again from humans and mosquitoes in the countries of Central Africa 
and Malaysia. The Zika virus belongs to the genus Flavivirus of the Flaviviridae family. It is 
a single-stranded RNA virus, with a shell and the shape of a sphere. Genomic comparisons 
have revealed that it has two major lineages: Asian and African on the basis of their nucleotide 
sequences. Typical symptoms are fever, headache, maculopapular rash that starts on the face 
and spreads to the whole body, redness in the eyes or conjunctivitis. Symptoms are generally 
mild and start about 2 or 7 days after the infection. Furthermore in some cases, lack of fever 
and often fewer symptoms such as muscle pain and arthralgia have been observed.
The Zika virus is a vector-borne disease, transmitted by several Aedes (stegomyia) species of 
mosquitoes, having been isolated in A. albopictus mosquitoes and A. aegypti. Other reported 
modes of transmission are through mother to fetus, through laboratory exposure, blood 
transfusion and through sexual contact. Transmission through transplantation is possible but 
not proven. The Zika virus has been detected in human blood, saliva, semen and urine. It has 
been confirmed that it remains after 62 days of infection in the patient’s semen and urine. A 
possible mode of transmission is considered to be the bite of infected animals with the virus. 
All these transmission modes of Zika virus make it a challenge for science and for the whole 
world.
Since the virus can be detected in human body fluids, various methods have been developed 
for diagnosing it, through saliva or urine samples that have been collected over 3–5 days after 
the onset of symptoms. It is possible to isolate the viral genome and detect the nucleic acid 
by reverse transcriptase-polymerase chain reaction. Serological tests like ELISA or immuno-
fluorescence are also widely used. CDC had developed an ELISA technique to detect specific 
anti-Zika IGM during the epidemic in Yap in 2007 [63].
Currently, no specific treatment or vaccination is available for Zika virus. Treatment of symp-
toms may include rest, fluids, antipyretics (the CDC advice against using aspirin or other non-
steroidal anti-inflammatory medication) and analgesics. In addition, the CDC has advised 
that pregnant women who are diagnosed with Zika virus should be considered for the moni-
toring of fetal growth and anatomy every 3–4 weeks, because of Zika virus correlation with 
infant microcephaly. Prevent Zika virus by avoiding mosquito bites. Mosquitoes that spread 
Zika virus bite mostly during the daytime. Additionally, sexual transmission of Zika virus 
can be prevented by using condoms or not having sex.
The geographical spread of the virus Zika virus beyond Africa and Asia was reported in 2007. 
The first major expansion with 185 cases occurred in 2007 on the Yap Islands of the Federated 
States of Micronesia. Scientists assume that the introduction of the virus in Yap probably came 
from an infected mosquito or human from Southeast Asia. In 2013, the virus broke out again 
near the French Polynesia. In May 2015, the Ministry of Health of Brazil sounded the alarm 
Current Topics in Zika40
because 14 states of the country were affected by the virus. Scientists suspect that Zika virus is 
the cause of 2400 cases of microcephaly and 29 infant deaths in Brazil only in 2015. Currently 
confirmed cases are in 31 countries of South America, 5 countries in Oceania/Pacific Islands 
and in Care Verde. Figure 1 represents all counties with active Zika virus this period March 
2016. The number is expected to increase due to the travel movements (holidays, Olympic 
Games, pilgrimage to Mecca). Furthermore, 80% of cases will not be diagnosed because they 
do not have any symptoms. The distribution of A. aegypti and A. albopictus has remarkable 
parallelisms with the spread of Zika virus.
The climate change has a great affect on the transmission of the Zika virus. A. aegypti is a 
known vector of several viruses, including dengue fever, yellow fever and Zika virus. They 
have identified hundreds of cases in Europe, some ended in death. Probably, it comes from 
Africa, having been transferred globally through trade and sailing ships. Now found in 
tropical, subtropical even in temperate parts. It is relatively small, with black and white pat-
terns. A distinctive external feature is the presence of a silver lyre-shaped sign on the chest. 
A. aegypti has four stages during its life: egg, larva, nymph and adult. In the first three stages, 
it lives in the water and in the last in the air. Females are hematophagous. They lay their eggs 
in temperatures between 25 and 29°C in small water-filled containers. In order to survive in 
a region, they must have adequate temperature and water availability. Humidity is vital not 
only for the eggs but also for the adults. They prefer to host mammals ideally humans [64] and 
artificial ponds. A. aegypti populations exist in northern Brazil, Southeast Asia, India, Greece, 
Spain and temperate regions of North America. Another type of mosquito that transmits dis-
eases and belongs to the same family is A. albopictus. It originates from the tropical forests of 
South-East Asia. They have the same appearance with A. aegypti, and the diagnostic feature 
is the presence of a median silver-scale line against a black background on the thorax. Their 
Figure 1. Areas with active Zika virus (colored dark grey, Category 1), areas with evidence of Zika virus (marked with 
small squares , Category 2) and areas with potential of Zika virus transmission (marked with large squares, Category 3). 
Figure was constructed based on WHO report of March 2017 about Zika virus.
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eggs can survive at −10°C, making them more resistant compared to A. aegypti. A. albopictus 
populations expand geographically over the years. The main reason for the enhanced distri-
bution of vectors A. aegypti and A. albopictus is climate change. Climate change has already 
changed the distribution of certain bodies of animals and is expected to influence it even 
further. According to the European Environment Agency, the global average temperature 
has increased by 0.74°C and the water level is increasing by 1.8 mm every year due to the fact 
that the ice in the Arctic melts at 2.7% each decade. Climate change may cause changes to 
the period and intensity of infectious diseases. The rise in temperature allows the survival of 
insects at higher altitudes. Proof of this can be malaria, which has expanded into areas, where 
previously it did not succeed. Dengue fever has also been seen in Puerto Rico, Florida, Gulf 
Coast states and Hawaii, places that had not usually been affected. Rising temperatures in the 
southern coast of the United States of America areas in Florida, Hawaii and the Coast state 
the following potential residence of A. aegypti together with Zika virus. The wind can reduce 
mosquito bites but also extend their flights. The increased rainfall creates small natural ponds, 
excellent conditions for reproduction and survival of mosquitoes. All these events create a 
clear picture that the protection of global health comes from environmental protection.
Another major factor that has an immediate effect on the transmission of the viruses is the 
mass population transfer from less safe areas to unaffected areas where they could find 
breeding ground for the expansion of the viruses [65]. The communities and the interna-
tional organizations should not be negative toward the population transfer from poorer to 
richer countries or from countries in war to countries in peace as long as extra measures are 
being taken like a database for all immigrants that enter another country, On the other hand, 
the technological achievements of the twenty-first century have annihilated the distances 
and many travelers can be easily transferred all over the globe [66]. Thus, new measures 
are necessary for the population control in all the vulnerable continents like Europe and 
Asia. In addition, an online webpage should be created in order to update on a daily basis 
about the new crusts in each continent for every virus from the ones mentioned above. A 
new more detailed profile for any incoming stigma should be created for every crust. The 
study of every specimen for the immediate tracking of dangerous mutations of the virus 
and the immediate report of different symptoms from the ones expected in case of detecting 
a familiar virus. Phylogeography of the viruses is a new revolutionary idea through which 
we can comprehend and compare the nature of the viruses for the better treatment in case 
of random outbreaks [67].
What do Zika virus and Ebola have in common? Although both Ebola and Zika virus have 
been known for decades, in the last period they have been in the forefront of international 
attention not only for their huge spread but also for the serious consequences they induced. 
Ebola is characterized as a deadly and highly contagious virus. On the other hand, Zika virus 
is not fatal but scientists associate it with microcephaly infants and Guillain-Barré syndrome. 
According to the World Health Organization, both Ebola and Zika virus are infectious dis-
eases that began and spread from animals to humans. Ebola is transmitted through infected 
animal and body fluids. Zika virus mainly through mosquito bites, from mother to fetus and 
isolated cases have reported transmission through semen and blood. The Ebola virus can 
only be transmitted when symptoms are present, the virus incubation period is from 2 to 
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21 days. We do not know if Zika virus is transmitted asymptotically, the incubation period of 
Zika virus has not been calculated exactly, but probably a few days to a week. Both viruses 
have mutated. Ebola causes several symptoms such as fever, vomiting and excessive bleeding 
while Zika virus exhibits mild symptoms or none, since 80% of the cases show no symptoms. 
It is worth to mention that there is neither treatment nor vaccine for both Ebola and Zika virus. 
Ebola is characterized by high mortality rates ranging from 50 to 90%. There are similarities in 
how these two epidemics unfold. Both of them were reported much later, many deaths from 
Ebola until declared an emergency for public health, and many microcephaly cases which 
are believed to be associated with Zika virus. Interesting is the similarities that geographical 
areas have which were inflicted by the two viruses. Ebola started and was mainly reported 
in Guinea, Sierra Leone and Liberia. These countries have a shortage of drinking water, resi-
dents have a poor diet, living in unsightly and unsanitary conditions and made use of pesti-
cides and chemicals. Most cases of Zika virus are found in Brazil, Columbia and El Salvador, 
poor countries with large rural areas, residents have a poor diet with a lack of vitamin A. In 
Brazil, the use of pesticides has increased and has forbidden chemicals from other countries. 
Similarities and differences between Ebola and Zika virus are shown in Table 2.
4. Conclusion
What Ebola and Zika virus should teach us is that we cannot assume that pathogenic viruses 
will continue to behave the same way without being mutated. Both viruses have similarities 
with how they spread. However, we should be mindful that there are some differences between 
Zika virus and Ebola based on fatality and modes of transmission. Zika virus like many of its 
cousins (WNV, dengue and chikungunya) will continue to exist and threaten mankind, until 
answers are provided to several open questions: Are there modes of transmission other than 
through the vector? Are mosquito species other than Aedes is involved in the urban cycle? Can 
person-to-person contamination occur through saliva? Can congenital or sexual transmission 
Similarities Differences
Both of them have been known by 
scientists for decades.
Zika virus typically leads to mild febrile cases, with most being 
asymptomatic, Ebola has severe symptoms.
They are an animal origin in other 
words, a zoonoses.
Ebola has high mortality rate Zika virus not.
No treatment or vaccine The incubation period of Ebola 2–21 of Zika virus few days up to a week
They spread in poor countries Zika virus cannot be transmitted through “casual contact”, as ebola
Had a rapid spread The Ebola can only be transmitted when symptoms are present.
They became epidemics in recent years.
Both viruses have mutated.
Table 2. Similarities and differences of viruses Zika virus end Ebola.
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Coast states and Hawaii, places that had not usually been affected. Rising temperatures in the 
southern coast of the United States of America areas in Florida, Hawaii and the Coast state 
the following potential residence of A. aegypti together with Zika virus. The wind can reduce 
mosquito bites but also extend their flights. The increased rainfall creates small natural ponds, 
excellent conditions for reproduction and survival of mosquitoes. All these events create a 
clear picture that the protection of global health comes from environmental protection.
Another major factor that has an immediate effect on the transmission of the viruses is the 
mass population transfer from less safe areas to unaffected areas where they could find 
breeding ground for the expansion of the viruses [65]. The communities and the interna-
tional organizations should not be negative toward the population transfer from poorer to 
richer countries or from countries in war to countries in peace as long as extra measures are 
being taken like a database for all immigrants that enter another country, On the other hand, 
the technological achievements of the twenty-first century have annihilated the distances 
and many travelers can be easily transferred all over the globe [66]. Thus, new measures 
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about the new crusts in each continent for every virus from the ones mentioned above. A 
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and the immediate report of different symptoms from the ones expected in case of detecting 
a familiar virus. Phylogeography of the viruses is a new revolutionary idea through which 
we can comprehend and compare the nature of the viruses for the better treatment in case 
of random outbreaks [67].
What do Zika virus and Ebola have in common? Although both Ebola and Zika virus have 
been known for decades, in the last period they have been in the forefront of international 
attention not only for their huge spread but also for the serious consequences they induced. 
Ebola is characterized as a deadly and highly contagious virus. On the other hand, Zika virus 
is not fatal but scientists associate it with microcephaly infants and Guillain-Barré syndrome. 
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eases that began and spread from animals to humans. Ebola is transmitted through infected 
animal and body fluids. Zika virus mainly through mosquito bites, from mother to fetus and 
isolated cases have reported transmission through semen and blood. The Ebola virus can 
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Current Topics in Zika42
21 days. We do not know if Zika virus is transmitted asymptotically, the incubation period of 
Zika virus has not been calculated exactly, but probably a few days to a week. Both viruses 
have mutated. Ebola causes several symptoms such as fever, vomiting and excessive bleeding 
while Zika virus exhibits mild symptoms or none, since 80% of the cases show no symptoms. 
It is worth to mention that there is neither treatment nor vaccine for both Ebola and Zika virus. 
Ebola is characterized by high mortality rates ranging from 50 to 90%. There are similarities in 
how these two epidemics unfold. Both of them were reported much later, many deaths from 
Ebola until declared an emergency for public health, and many microcephaly cases which 
are believed to be associated with Zika virus. Interesting is the similarities that geographical 
areas have which were inflicted by the two viruses. Ebola started and was mainly reported 
in Guinea, Sierra Leone and Liberia. These countries have a shortage of drinking water, resi-
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occur? What is the rate of transmission by blood transfusions? Is ZIKV capable of establish-
ing a chronic infection? Is there the generation of a long-lived protective immune response? Is 
there the possibility of re-infection? These questions must be urgently answered to allow the 
effective design of strategies to prevent and/or treat ZIKV transmission and infection and will 
demand a collective and coordinate basic research initiative to address these issues.
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Abstract
We describe and discuss the rationale, design and current implementation of a model for
an integrated intervention for the primary and secondary prevention of Zika and other
Aedes-borne diseases and sexually transmitted infections that impact reproductive
health, pregnancy and perinatal life stages in women and their families in Merida,
Mexico. The intervention includes enhanced surveillance of pregnant women, imple-
mentation of communication strategies to promote good practices to prevent disease
transmission, determination of the frequency of structural anomalies detected prenatally
in the foetus, umbilical cord and placenta of pregnancies diagnosed with ZIK infection,
detection of ZIKV and other arboviruses/viruses in products of abortion, in-utero and
early newborn, provision of Aedes aegypti-proof houses” (protecting homes with door/
window screens with insecticide to prevent the access of mosquitoes), mosquito repellents,
larvicides and education/promotion of best practices for the prevention of infection with
dengue (DENV), chikungunya (CHIKV) and Zika (ZIKV) and an anthropological studies
on sociocultural factors of pregnant women associated with ZIKV. This intervention is
being developed in a population of 10,000 people of the city of Merida and with the
participation of a multidisciplinary group of public health professionals in collaboration
with the Ministry of Health and the Government of Yucatan.
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1. Introduction
Dengue (DEN), chikungunya (CHIK) and now Zika (ZIKV) are Aedes-borne diseases (ABD) in
different transmission stages in southern Mexico, that is, endemic (DEN), epidemic (CHIK) and
emergent (ZIKV), that account for increasing number of cases, chronic disability conditions and
deaths along with the threat of increasing numbers of congenital disorders. While ABD face the
operational problems associated to the control the mosquito vector Aedes aegypti, ZIKV infection
has also a non-vectorial transmission route: vertical (transplacental and birth), sexual and/or by
blood transfusion which may compromise the health of the mother, fetus and the newborn [1].
The first outbreak of ZIKV outside of Africa and Asia was in Micronesia and affected 72% of
the population in 2007 [2] and was confirmed by Centers for Disease Control and Prevention
(CDC) [2, 3]. Transmission of (ZIKV) spread to Malaysia, the Philippines and French Polynesia.
In 2013–2014, French Polynesia reported a ZIKV outbreak reaching 60% of the popu-lation
[2–5]. In 2015, Brazil had an outbreak of ZIKV with 134,057 confirmed cases, were fatal and
80% were asymptomatic [6]. Colombia reported more than 65,000 positive cases of ZIKV
during the first half of 2016 [7]. The outbreak of ZIKV in Mexico started at the end of 2015 in
Chiapas where 8842 confirmed cases were reported by June of 2017. The Yucatan state, also in
south Mexico, has reported 1295 cases and most of confirmed Zika infections in pregnant
women (921 confirmed cases) in Mexico [6, 8, 9].
Recent ZIKV epidemiological alerts associate ZIKV/pregnancy with fetal/neonatal morbidity
and mortality because there was a marked increase in newborns that developed microcephaly
during the ZIKV outbreak in Brazil. By the end of 2015, detection by RNA sequencing of ZIKV
from amniotic fluid of foetuses with disorders in the central nervous system was the key for
the World Health Organization (WHO) to declare the ZIKVa public health emergency [10–12].
Actually, congenital Zika syndrome (CZS) involves craniofacial malformations (microcephaly,
craniofacial anomalies and facial dysmorphism), foetal brain disruption sequence and neural
tube defects [13–16]. DEN and CHIK as well, are associated with spontaneous abortion,
prematurity and congenital diseases, and the newborn may present thrombocytopenia, hepa-
tomegaly and develop neurological disorders.
The virus has been documented in body fluids as blood, tears, breast milk, vaginal discharge,
semen and tissues from abortions and stillbirths [17, 18]. Confirmation of infectious diseases
through laboratory diagnostic tests are often necessary; the arrival of ZIKV infection made that
the tools developed for other flaviviruses such as DEN, based on immune response (IgM, IgG),
would generate false positives to ZIKV. There are several working groups that are developing
more specific and sensitive IgM and IgG tests, so it is essential to be definite of the final
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diagnosis, due to the possible consequences that could involve a false positive or false negative
diagnosis. The polymerase chain reaction (PCR) has become the main mechanism for the diag-
nosis of ZIKV nuclei acid; however, compared to the viral particles of DEN and CHIK, the viral
particles of ZIKV are low and therefore the period to give a positive diagnosis in serum is very
short and challenging. Other possibilities are detection in urine saliva, breast milk and semen, in
pregnant women and their spouses, where a longer viremia is reported [17–20].
This situation challenges vector control and the surveillance system, the prevention of trans-
mission and the organization of health care systems that should effectively deal with the
concurrence of three diseases with different clinical outcomes and a common vehicle of
transmission. Major challenges include the establishment of a comprehensive communica-
tion strategy to sensitize and provide information regarding the risk of ZIKV infection in
pregnant women, and the early detection and confirmation of arboviral diseases in the target
group (pregnant women) in order to launch the preventive and control interventions. Addi-
tional challenges include the improvement or prenatal, pregnancy and newborn care in
primary health care centers and hospitals as well as strengthening the surveillance of ABD
in these areas.
We need to implement integrated strategies that can improve detection of infection and special
medical care for infected women, the follow-up of newborn at risk and the best preventive and
vector control measures. Herein, we describe and discuss the design and current implementa-
tion of an integrated model for primary and secondary preventive interventions for ZIKV,
along with other ABD and sexually transmitted infections, that impact reproductive health,
pregnancy and perinatal life stages in women and their upspring in Merida, Mexico.
We describe the rationale, components, implementation and evaluation of this intervention,
which includes:
• Enhanced surveillance of pregnant women, including the early detection of infectious
diseases such as syphilis, HIV and DEN/CHIK/ZIKV.
• Implementation of communication strategies, that is, prevention and control measures
against the bite of the mosquito vectors, family-planning strategies.
• Determination of the frequency of structural anomalies detected prenatally in the fetus,
umbilical cord and the placenta of pregnancies affected by infection with ZIKV.
• Detection of ZIKV, and other arboviruses/viruses in products of abortion, in-utero and
early newborn.
• Implementation of the strategy “Casas a prueba de Aedes aegypti/Aedes aegypti-proof
houses” in Yucatan (protecting homes and families with door/window screening to prevent
the access of mosquitoes), provision of mosquito repellents and larvicides, and education/
promotion of best practices for the prevention of infection with DEN, CHIK and ZIKV.
• Conducting an anthropological research of sociocultural factors associated with Zika virus.
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1. Introduction
Dengue (DEN), chikungunya (CHIK) and now Zika (ZIKV) are Aedes-borne diseases (ABD) in
different transmission stages in southern Mexico, that is, endemic (DEN), epidemic (CHIK) and
emergent (ZIKV), that account for increasing number of cases, chronic disability conditions and
deaths along with the threat of increasing numbers of congenital disorders. While ABD face the
operational problems associated to the control the mosquito vector Aedes aegypti, ZIKV infection
has also a non-vectorial transmission route: vertical (transplacental and birth), sexual and/or by
blood transfusion which may compromise the health of the mother, fetus and the newborn [1].
The first outbreak of ZIKV outside of Africa and Asia was in Micronesia and affected 72% of
the population in 2007 [2] and was confirmed by Centers for Disease Control and Prevention
(CDC) [2, 3]. Transmission of (ZIKV) spread to Malaysia, the Philippines and French Polynesia.
In 2013–2014, French Polynesia reported a ZIKV outbreak reaching 60% of the popu-lation
[2–5]. In 2015, Brazil had an outbreak of ZIKV with 134,057 confirmed cases, were fatal and
80% were asymptomatic [6]. Colombia reported more than 65,000 positive cases of ZIKV
during the first half of 2016 [7]. The outbreak of ZIKV in Mexico started at the end of 2015 in
Chiapas where 8842 confirmed cases were reported by June of 2017. The Yucatan state, also in
south Mexico, has reported 1295 cases and most of confirmed Zika infections in pregnant
women (921 confirmed cases) in Mexico [6, 8, 9].
Recent ZIKV epidemiological alerts associate ZIKV/pregnancy with fetal/neonatal morbidity
and mortality because there was a marked increase in newborns that developed microcephaly
during the ZIKV outbreak in Brazil. By the end of 2015, detection by RNA sequencing of ZIKV
from amniotic fluid of foetuses with disorders in the central nervous system was the key for
the World Health Organization (WHO) to declare the ZIKVa public health emergency [10–12].
Actually, congenital Zika syndrome (CZS) involves craniofacial malformations (microcephaly,
craniofacial anomalies and facial dysmorphism), foetal brain disruption sequence and neural
tube defects [13–16]. DEN and CHIK as well, are associated with spontaneous abortion,
prematurity and congenital diseases, and the newborn may present thrombocytopenia, hepa-
tomegaly and develop neurological disorders.
The virus has been documented in body fluids as blood, tears, breast milk, vaginal discharge,
semen and tissues from abortions and stillbirths [17, 18]. Confirmation of infectious diseases
through laboratory diagnostic tests are often necessary; the arrival of ZIKV infection made that
the tools developed for other flaviviruses such as DEN, based on immune response (IgM, IgG),
would generate false positives to ZIKV. There are several working groups that are developing
more specific and sensitive IgM and IgG tests, so it is essential to be definite of the final
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diagnosis, due to the possible consequences that could involve a false positive or false negative
diagnosis. The polymerase chain reaction (PCR) has become the main mechanism for the diag-
nosis of ZIKV nuclei acid; however, compared to the viral particles of DEN and CHIK, the viral
particles of ZIKV are low and therefore the period to give a positive diagnosis in serum is very
short and challenging. Other possibilities are detection in urine saliva, breast milk and semen, in
pregnant women and their spouses, where a longer viremia is reported [17–20].
This situation challenges vector control and the surveillance system, the prevention of trans-
mission and the organization of health care systems that should effectively deal with the
concurrence of three diseases with different clinical outcomes and a common vehicle of
transmission. Major challenges include the establishment of a comprehensive communica-
tion strategy to sensitize and provide information regarding the risk of ZIKV infection in
pregnant women, and the early detection and confirmation of arboviral diseases in the target
group (pregnant women) in order to launch the preventive and control interventions. Addi-
tional challenges include the improvement or prenatal, pregnancy and newborn care in
primary health care centers and hospitals as well as strengthening the surveillance of ABD
in these areas.
We need to implement integrated strategies that can improve detection of infection and special
medical care for infected women, the follow-up of newborn at risk and the best preventive and
vector control measures. Herein, we describe and discuss the design and current implementa-
tion of an integrated model for primary and secondary preventive interventions for ZIKV,
along with other ABD and sexually transmitted infections, that impact reproductive health,
pregnancy and perinatal life stages in women and their upspring in Merida, Mexico.
We describe the rationale, components, implementation and evaluation of this intervention,
which includes:
• Enhanced surveillance of pregnant women, including the early detection of infectious
diseases such as syphilis, HIV and DEN/CHIK/ZIKV.
• Implementation of communication strategies, that is, prevention and control measures
against the bite of the mosquito vectors, family-planning strategies.
• Determination of the frequency of structural anomalies detected prenatally in the fetus,
umbilical cord and the placenta of pregnancies affected by infection with ZIKV.
• Detection of ZIKV, and other arboviruses/viruses in products of abortion, in-utero and
early newborn.
• Implementation of the strategy “Casas a prueba de Aedes aegypti/Aedes aegypti-proof
houses” in Yucatan (protecting homes and families with door/window screening to prevent
the access of mosquitoes), provision of mosquito repellents and larvicides, and education/
promotion of best practices for the prevention of infection with DEN, CHIK and ZIKV.
• Conducting an anthropological research of sociocultural factors associated with Zika virus.
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2. Enhanced surveillance of pregnant women, including the early detection
of infectious diseases such as syphilis, HIVand DEN/CHIK/ZIKV
In Merida, a strong collaborative work with local authorities is already in place with interven-
tions targeting high-risk areas and vulnerable populations. These efforts were initially orga-
nized for DEN control due to its endemic transmission in the area. Due to the introduction of
CHIK in early 2014, and the most recent introduction of ZIKV, the program has extended to
address these three ABD with major emphasis in ZIKV infection due to its high impact in the
newborn. “Familias sin Dengue project” (Figure 1) (financed by SANOFI-Pasteur) has
established a platform for the surveillance ad early detection of dengue infection that will be
used to improve detection of ZIKV infection in target women.
2.1. Surveillance of ZIKVand urban Aedes-borne diseases (ABD) with in the cohort study
“Familias sin dengue”
For Merida, the team has access to datasets containing the residential address of ~25,000 DEN
and ~5000 CHIK cases reported during 2011–2016 including the study area. The Cohort study:
“Familias sin Dengue” also provides a group of women in reproductive age who will be follow
through house visits in order to detect suspicion of ZIKV infection.
ZIKV infection in the general population presents with a mild disease that remit in 3–7 days.
ABD are endemic in Yucatan, and congenital infections result from the transmission of
Figure 1. Identification logo of the project families without dengue.
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infection from the mother to the foetus during pregnancy. Therefore, in populations with an
epidemiological association of ZIKV, pregnant women should be intentionally evaluated for
ZIKV during the development of clinical manifestations similar to those described [11]. It is
essential to establish a correct diagnosis in the pregnant woman due to the poor information
generated on the transmission, pathophysiology and diagnosis of the impact that this infec-
tion has on the product of gestation [10, 21].
The virus in addition to being identified in saliva, blood, semen, urine, in breast milk, has also
been found, but it is not known, if breastfeeding can affect the baby. But if vertical transmission
has been demonstrated through amniocentesis, with confirmation the presence of ZIKV by
PCR and reported lesions vary according to the time of infection and time of pregnancy.
However, information about ZIKV infection proximate to the conception period is scarce.
Women who are positive should have a follow-up for the search for morphological abnormal-
ities in their products. Zika infection in the mother with transmission to the fetus, causing a
group of structural abnormalities of at least the central nervous system (CNS), which produces
a sequence of cerebral disruption and causes a functional disability secondary to damage, is
denominated congenital Zika syndrome (CZS) [13, 22–24].
Enhanced surveillance searches for prenatal and/or neonatal morphological abnormalities in
all products of pregnancies affected by ZIKV. This performed by perinatologists specialized in
fetal medicine and geneticists from the dysmorphological approach. A family history is made
of all the patients with the purpose of obtaining a history of genetic diseases or the use of
teratogens that may imply in the diagnosis of maternal-fetal health.
According to the guidelines established by the CDC, there is no optimal time to perform an
ultrasonographic screening to detect microcephaly. On a daily basis, ultrasound surveil-
lance to detect structural abnormalities in a pregnancy is performed among the 18–20 weeks
of gestation [25]. Ultrasonographic follow-up should be performed from the beginning of
the ZIK symptomatology in the mother with a monthly monitoring depending on the
prenatal manifestations found. The variables investigated are intrauterine growth, cephalic
perimeter, central nervous system abnormalities and other structural abnormalities as
well as the presence of intracerebral and/or placental calcifications and the amount of
amniotic fluid.
Upon ultrasonographic findings of malformations in the product, the patient will be informed,
who will decide whether or not to follow the pregnancy. In case of a request for the interruption
of the pregnancy the case will be evaluated by a Bioethics Committee to define the resolution.
Pregnancies with or without ZIKV infection that culminate in abortion or early foetal death,
with prior informed consent, will be performed a genetic clinical evaluation, with collection
of body images, and evisceration or autopsy will be performed, as the case may be, to
obtain brain tissue, hepatic, cardiac and renal, to perform histopathological study and RT-
PCR for ZIKV nuclei acid in frozen and fixed tissue. The mother will be informed of the
findings and genetic counseling on care and risk will be given to reduce birth defects
in subsequent pregnancies. To date, there is no contraindication to vaginal delivery and
breastfeeding.
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of all the patients with the purpose of obtaining a history of genetic diseases or the use of
teratogens that may imply in the diagnosis of maternal-fetal health.
According to the guidelines established by the CDC, there is no optimal time to perform an
ultrasonographic screening to detect microcephaly. On a daily basis, ultrasound surveil-
lance to detect structural abnormalities in a pregnancy is performed among the 18–20 weeks
of gestation [25]. Ultrasonographic follow-up should be performed from the beginning of
the ZIK symptomatology in the mother with a monthly monitoring depending on the
prenatal manifestations found. The variables investigated are intrauterine growth, cephalic
perimeter, central nervous system abnormalities and other structural abnormalities as
well as the presence of intracerebral and/or placental calcifications and the amount of
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Upon ultrasonographic findings of malformations in the product, the patient will be informed,
who will decide whether or not to follow the pregnancy. In case of a request for the interruption
of the pregnancy the case will be evaluated by a Bioethics Committee to define the resolution.
Pregnancies with or without ZIKV infection that culminate in abortion or early foetal death,
with prior informed consent, will be performed a genetic clinical evaluation, with collection
of body images, and evisceration or autopsy will be performed, as the case may be, to
obtain brain tissue, hepatic, cardiac and renal, to perform histopathological study and RT-
PCR for ZIKV nuclei acid in frozen and fixed tissue. The mother will be informed of the
findings and genetic counseling on care and risk will be given to reduce birth defects
in subsequent pregnancies. To date, there is no contraindication to vaginal delivery and
breastfeeding.
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2.2. Studies for the core group
The core group of the study are the pregnant women of two interventions; the cohort study
(Figure 2): “families without dengue” (Figure 1) and “Aedes aegypti-proof houses” (Figure 3) in
which previous informed and signed consent, with clarity the commitments that the group of
professionals, as well as the participant and their family have.
When a pregnant woman, her partner and family enter the project, the following diagnostic
tests and complementary studies are carried out (Figure 4):
A. Molecular detection of ZIKV is performed with the use of the Trioplex Real time RT-PCR
Assay from the Centers for Disease Control and Prevention (CDC), for detection and
differentiation of RNA from DEN, CHIK and ZIKV in serum and urine, to all members
of the family.
B. Serum and urine studies with Trioplex RT-PCR monthly to the pregnant woman and her
partner throughout pregnancy.
C. HIV and VDRL (syphilis) tests on the pregnant woman and her partner.
D. TORCH (toxoplasma, rubeola, cytomegalovirus and herpes) to the pregnant.
Figure 2. Map of the study areas in Merida, Yucatan, Mexico. (A) Map of Mexico with the location of the city Merida; (B)
distribution of the participants of the cohort from the project families without dengue; (C) intervention area in the
neighborhood Juan Pablo II.
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E. Blood count, blood chemistry, general urine test and erythrocyte folate profile in the
pregnant woman.
F. Obstetric ultrasound (quarterly).
2.3. Positive cases for ZIKV
In case the participant or any member of the family has signs and symptoms compatible with
DEN/CHIK/ZIKV, and have positive test result of: diagnostic test Trioplex RT-PCR DEN, CHIK
and ZIKV and serological tests of NS1 and IgG for dengue, IgM DEN, CHIK and ZIKV [20].
Figure 3. Identification logo of the intervention ‘Aedes aegypti-proof houses’.
Figure 4. Carnet for pregnant women: (a) front cover with general information of the project and how to contact the team
including a free telephonic number to communicate in case of presenting symptoms compatible with DEN/ CHIK/ ZIKV
and (b) record for diagnostic tests and complementary studies that are recommended for pregnant women.
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At the moment that the pregnant woman presents a positive result to ZIKV by the Trioplex RT-
PCR assay for DEN, CHIK and ZIKV, she is informed of the diagnosis with counselling and
psychological support in case of requesting it and the following studies and assessments are
requested:
A. Liver function tests.
B. Structural ultrasound/obstetric ultrasound (monthly).
C. Genetic consultation.
D. Obstetric consultation.
E. Amniocentesis with karyotype and diagnostic test Trioplex RT-PCR assay for DEN, CHIK
and ZIKV, if required.
At the end of the pregnancy, vaginal, cesarean or abortion, biological samples will be collected








3. Implementation of communication strategies, that is, prevention and
control measures against the bite of the mosquito vectors, family-planning
strategies
3.1. Preventive kits
All pregnant women will be provided with an educational/preventive kit containing (Figure 5):
1. Proven repellent (DEET 30%) recommended by CENAPRECE (Ministry of Health) for
protection outside the home.
2. Organic and environmentally friendly larvicide recommendedbyCENAPRECE (SPINOSAD).
3. Educational brochure for the promotion of good practices to avoid the risk of mosquito
bites (including use of repellent) and for the elimination and control of Aedes breeding
grounds (including the use of larvicides).
4. Thermometer for fever monitoring.
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5. Personal symptom monitoring card compatible with ZIKV and Carnet for registration of
laboratory tests.
6. Condoms (for prevention of possible transmission by sexual practices).
7. Access to 01800 CERO ZIKA (01800 09452) for report in case the pregnant or someone in
your family presents symptoms of Zika: erythema, fever, conjunctivitis or joint pain.
To supplement these direct actions, text messages are periodically sent with information
relevant to the case and reinforce preventive measures and home visits in search of febrile
illnesses. Those women residing in the area where the “Aedes aegypti-proof houses” strategy
will be evaluated will also receive the installation of long-lasting insecticide nets permanently
installed in doors and windows in their homes (see more detail in the next section).
3.2. Educational intervention with women of reproductive age and their partners for the
prevention of vector-borne diseases and sexually transmitted infections
The strategy of educational intervention is performed in the form of workshops. A “a peda-
gogical strategy, apparently simple, that by a learning methodology by doing in group, allows
to build meaning to those” someone “who participate in it in order to learn and know”
something “, from the integral insertion in the process” [26].
It is directed to the pregnant women who participate in the project and the women who are at
reproductive age within the family nuclei. Workshops are also held with their partners so that
Figure 5. Prevention kits for pregnant women.
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they are also aware of the information and are involved in the corresponding care during
pregnancy. Basically, workshops deliver topics related to health, body, sexuality, pregnancy
and strategies for prevention of vector-borne diseases and sexually transmitted infections.
The themes and objectives of the workshop are:
Topic 1. Body, pregnancy and sexuality.
General objective: to recognize the characteristics of the male and female body that make
possible a pregnancy and the processes of a normal pregnancy, to identify the benefits of a
planned pregnancy, the repercussions of an unplanned pregnancy, the health risks during
pregnancy and to recognize the importance of prenatal care.
Topic 2. Aedes-borne diseases and the presence of ZIKV in pregnancy.
General objective: to provide information for the prevention of DEN, CHIK and ZIK, as well as
the impact of this during pregnancy, identify the mechanisms of transmission:
A. Symptoms and signs of dengue, chikungunya and Zika.
B. Identify the activities they do and can do at home and in the community to prevent
Aedes-borne diseases.
C. Impact of Zika infection on pregnancy. Congenital malformations.
D. Promotion of the use of condoms as a method of prevention of Zika.
E. Recognize the importance of preventing Zika during pregnancy.
F. Recognize Zika as a preventable disease and not as a determinant for the presence of
congenital malformations.
Topic 3. HIV/STIs prevention.
Course objective: identify the risks of STI contagion with an emphasis on HIV.
A. Myths and realities.
B. Describe themost frequent STIs:HIV, gonorrhea, syphilis, herpes, andhumanpapillomavirus.
C. Mention what are the risk practices and routes of HIV and STI transmission.
D. Describe clinical picture (differences between HIV/AIDS and STIs) and diagnostic
methods, treatment and prognosis.
E. Identify methods of prevention of STIs (male condom, female condom, and abstinence.
Topic 4. Protected sex.
Course objective: Provide information on the male and female condom, and promote its use.
A. Perception of risks of contracting STIs.
B. Myths and realities.
C. Knowledge and importance of protected sex.
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D. Promote the practice of sex protected in sexually active population.
E. Knowledge, characteristics and correct use of the male and female condom.
F. Explain the correct use of the female condom (steps for its use).
Topic 5. Self-care of health.
General objective: To reflect on the self-care practices of health, identifying the consequences,
and benefits of self-care.
4. Determination of the frequency of structural anomalies detected
prenatally in the foetus, umbilical cord, and the placenta of pregnancies
affected by infection with ZIKV
Gestation products that come to term should be evaluated for a possible congenital infection
by ZIKV. Serum, placenta tissue, and urine should be obtained. The search for ZIKV RNA,
immunoglobulin M and neutralizing ZIKVantibodies as well as neutralizing antibodies and M
immunoglobulins for DEN is indicated. Tissue collection should be done within the first 2 days
of life, if possible [11]. For this reason, all pregnancy products are evaluated by a group of
experts, including clinical geneticists and pathologists, and the tissues are collected and evalu-
ated within the first 12 hours of life. The tissues are sent to the pathology service for histopath-
ological evaluation of the placenta and the umbilical cord. Immunohistochemical staining is
performed in fixed tissue and ZIKV RNA is sought by RT-PCR in fixed and frozen tissue.
Clinical evaluation implies a dysmorphlogical approach and records gestational age, Apgar,
occipitofrontal perimeter, height and weight. Neurological, craniofacial features, cutaneous,
thoracic, and abdominal abnormalities are recorded. If a specific abnormality is observed, an
evaluation by the appropriate specialist is requested [14]. Complementary studies are carried
out such as transfontanellar ultrasound, auditory, and neonatal screening.
Long-term follow-up involves evaluation for 18 months and includes follow-up by geneticist,
pediatrician, pediatric ophthalmology, audiologyandpediatric neurology.Amedical record of occi-
pitofrontal circumference (OFC), growth,weight, height and neuromotor development is kept [16].
The possible clinical scenarios to evaluate are:
1. The patient who is observed without microcephaly or morphological alterations and has
normal neurological development being the mother of a child without or with infection by
ZIK and
2. Those that are observed with microcephaly, morphological alterations and / or alterations of
the neuromotor development being children of mothers without or with infection or ZIKV.
In the latter group, previously well-established genetic syndromes, added teratogenic causes
and/or complementary genetic studies would be ruled out according to the individual needs of
each one.
The information will be collected in a database to be able to determine the frequencies.
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E. Recognize the importance of preventing Zika during pregnancy.
F. Recognize Zika as a preventable disease and not as a determinant for the presence of
congenital malformations.
Topic 3. HIV/STIs prevention.
Course objective: identify the risks of STI contagion with an emphasis on HIV.
A. Myths and realities.
B. Describe themost frequent STIs:HIV, gonorrhea, syphilis, herpes, andhumanpapillomavirus.
C. Mention what are the risk practices and routes of HIV and STI transmission.
D. Describe clinical picture (differences between HIV/AIDS and STIs) and diagnostic
methods, treatment and prognosis.
E. Identify methods of prevention of STIs (male condom, female condom, and abstinence.
Topic 4. Protected sex.
Course objective: Provide information on the male and female condom, and promote its use.
A. Perception of risks of contracting STIs.
B. Myths and realities.
C. Knowledge and importance of protected sex.
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D. Promote the practice of sex protected in sexually active population.
E. Knowledge, characteristics and correct use of the male and female condom.
F. Explain the correct use of the female condom (steps for its use).
Topic 5. Self-care of health.
General objective: To reflect on the self-care practices of health, identifying the consequences,
and benefits of self-care.
4. Determination of the frequency of structural anomalies detected
prenatally in the foetus, umbilical cord, and the placenta of pregnancies
affected by infection with ZIKV
Gestation products that come to term should be evaluated for a possible congenital infection
by ZIKV. Serum, placenta tissue, and urine should be obtained. The search for ZIKV RNA,
immunoglobulin M and neutralizing ZIKVantibodies as well as neutralizing antibodies and M
immunoglobulins for DEN is indicated. Tissue collection should be done within the first 2 days
of life, if possible [11]. For this reason, all pregnancy products are evaluated by a group of
experts, including clinical geneticists and pathologists, and the tissues are collected and evalu-
ated within the first 12 hours of life. The tissues are sent to the pathology service for histopath-
ological evaluation of the placenta and the umbilical cord. Immunohistochemical staining is
performed in fixed tissue and ZIKV RNA is sought by RT-PCR in fixed and frozen tissue.
Clinical evaluation implies a dysmorphlogical approach and records gestational age, Apgar,
occipitofrontal perimeter, height and weight. Neurological, craniofacial features, cutaneous,
thoracic, and abdominal abnormalities are recorded. If a specific abnormality is observed, an
evaluation by the appropriate specialist is requested [14]. Complementary studies are carried
out such as transfontanellar ultrasound, auditory, and neonatal screening.
Long-term follow-up involves evaluation for 18 months and includes follow-up by geneticist,
pediatrician, pediatric ophthalmology, audiologyandpediatric neurology.Amedical record of occi-
pitofrontal circumference (OFC), growth,weight, height and neuromotor development is kept [16].
The possible clinical scenarios to evaluate are:
1. The patient who is observed without microcephaly or morphological alterations and has
normal neurological development being the mother of a child without or with infection by
ZIK and
2. Those that are observed with microcephaly, morphological alterations and / or alterations of
the neuromotor development being children of mothers without or with infection or ZIKV.
In the latter group, previously well-established genetic syndromes, added teratogenic causes
and/or complementary genetic studies would be ruled out according to the individual needs of
each one.
The information will be collected in a database to be able to determine the frequencies.
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Patients who undergo microcephaly and/or brain disruption sequence will be given skull CT
and brain MRI to define CNS damage and its relationship to congenital infection by ZIKV.
Other interventions will be required according to the needs of each individual [27]. Other
interventions will be required according to the needs of each individual, such as the evaluation
by a paediatric cardiologist in the assumption of a cardiac murmur or paediatric nephrologist
for renal morphological abnormalities that compromise the function.
5. Effective vector control interventions for integrated prevention/control
of Aedes-borne diseases (ABD) including DEN/CHIK/ZIKVand targeted
on vulnerable population (pregnant women)
As described previously, the project is working to ensure that vulnerable population (pregnant
women and their families) are provided with the best possible support and care, including the
access of the best supplies for vector control and the prevention of Aedes-borne diseases (ABD);
this is personal and family protection in addition to the traditional activities performed by the
local health programs. This was urged in the Zika strategic response framework and joint
operations plan emitted by WHO [28], commending a proactive special care for pregnant
women, such as giving adequate repellent lotion and treated mosquito nets.
5.1. How can pregnant women protect themselves from mosquito bites?
The best protection from ZIKV is preventing mosquito bites. As stated by the most important
agencies worldwide such as the World Health Organization [29], the CDC [30], and the
Ministry of Health in Mexico, this can be done effectively and individually (and at the family
level) by the integrated use of: insect repellents, the use of physical barriers such as screens on
doors and windows to prevent mosquito bites outside and inside home; in an integrated
manner with the elimination of mosquito breeding sites, the application of larvicides and
application of insecticides to kill adult mosquitoes to control vector populations in and around
homes [31].
5.2. The entomological tools and interventions selected
For an effective and integrated prevention/control of ABD in this project we have chosen: the
best repellent with diethyltoluamide (DEET) available in the local market, the intervention
called “Aedes aegypti-proof houses” (“Casas a prueba de Aedes aegypti” in Spanish) which
involves insecticide-treated house screening (ITS) with use long-lasting insecticidal nets (LLIN)
permanently fitted to windows and doors to exclude A. aegypti, from houses, and the provision
of an environmentally safe biorational larvicide.
5.3. Repellent
In order to select the best repellent for this project, we assessed the efficacy of commercial
repellents available in Yucatan against A. aegypti. First results were reported by Uc-Puc et al.
[32]. Protection time was determined based on WHO/CTD/WHOPES/IC and Mexican
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regulations (NOM-032-SSA2–2014) [32–34]. Two products, both with DEET (N,N-diethyl-3-
methylbenzamide) >25% met the recommended protection (≥6 hours). The best repellent was
“Stop fly bung” with DEET at 30%. Efficacy was directly proportional to the concentration of
DEET; botanicals repellents resulted no protective. Repellents with DEET provided more
protection against A. aegypti and botanical repellents, including impregnated wristbands pro-
vided no protection [33, 34].
5.4. Larvicide
The selection of the larvicide was supported by previous evaluations of its efficacy under labora-
tory and field conditions and in consistency with the list of available products recommended by
the Mexican Ministry of Health [35–38]. The product selected was the biorational and environ-
mentally friendly larvicide Natular® DT (Spinosad 7.48%; Clarke Mosquito Control, IL, USA;
WHOPES approved) which is available in the formulation of a tablet for containerized water.
This product and formulation is a highly effective larvicide againstA. aegyptiwith a residuality of
9 weeks in field studies. In addition is non-toxic to humans, and also an option for the manage-
ment of insecticide resistance for local A. aegypti populations.
5.5. Aedes aegypti-proof houses
The intervention called Aedes aegypti-proof houses (“Casas a prueba de Aedes aegypti”) involves
insecticide-treated house screening (ITS) with use long-lasting insecticidal nets (LLIN) perma-
nently fitted to windows and doors to exclude A. aegypti, vector of dengue, chikungunya and
Zika (Figure 6).
The selection of these interventions was based on previous studies of our group. Briefly, from
2009 to 2014, cluster randomized controlled trials were conducted in the Mexican cities of
Acapulco and Merida. Intervention clusters received Aedes aegypti-proof houses with ITS and
followed-up during 2 years. Overall, results showed significant and sustained reductions on
adult vector densities in houses in the treated clusters with ITS after 2 years: ca. 50% on the
presence (OR ≤ 0.62, P < 0.05) and abundance (IRR ≤ 0.58, P < 0.05) of indoor-resting adults. ITS
Figure 6. Aedes aegypti-proof houses.
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Patients who undergo microcephaly and/or brain disruption sequence will be given skull CT
and brain MRI to define CNS damage and its relationship to congenital infection by ZIKV.
Other interventions will be required according to the needs of each individual [27]. Other
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by a paediatric cardiologist in the assumption of a cardiac murmur or paediatric nephrologist
for renal morphological abnormalities that compromise the function.
5. Effective vector control interventions for integrated prevention/control
of Aedes-borne diseases (ABD) including DEN/CHIK/ZIKVand targeted
on vulnerable population (pregnant women)
As described previously, the project is working to ensure that vulnerable population (pregnant
women and their families) are provided with the best possible support and care, including the
access of the best supplies for vector control and the prevention of Aedes-borne diseases (ABD);
this is personal and family protection in addition to the traditional activities performed by the
local health programs. This was urged in the Zika strategic response framework and joint
operations plan emitted by WHO [28], commending a proactive special care for pregnant
women, such as giving adequate repellent lotion and treated mosquito nets.
5.1. How can pregnant women protect themselves from mosquito bites?
The best protection from ZIKV is preventing mosquito bites. As stated by the most important
agencies worldwide such as the World Health Organization [29], the CDC [30], and the
Ministry of Health in Mexico, this can be done effectively and individually (and at the family
level) by the integrated use of: insect repellents, the use of physical barriers such as screens on
doors and windows to prevent mosquito bites outside and inside home; in an integrated
manner with the elimination of mosquito breeding sites, the application of larvicides and
application of insecticides to kill adult mosquitoes to control vector populations in and around
homes [31].
5.2. The entomological tools and interventions selected
For an effective and integrated prevention/control of ABD in this project we have chosen: the
best repellent with diethyltoluamide (DEET) available in the local market, the intervention
called “Aedes aegypti-proof houses” (“Casas a prueba de Aedes aegypti” in Spanish) which
involves insecticide-treated house screening (ITS) with use long-lasting insecticidal nets (LLIN)
permanently fitted to windows and doors to exclude A. aegypti, from houses, and the provision
of an environmentally safe biorational larvicide.
5.3. Repellent
In order to select the best repellent for this project, we assessed the efficacy of commercial
repellents available in Yucatan against A. aegypti. First results were reported by Uc-Puc et al.
[32]. Protection time was determined based on WHO/CTD/WHOPES/IC and Mexican
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regulations (NOM-032-SSA2–2014) [32–34]. Two products, both with DEET (N,N-diethyl-3-
methylbenzamide) >25% met the recommended protection (≥6 hours). The best repellent was
“Stop fly bung” with DEET at 30%. Efficacy was directly proportional to the concentration of
DEET; botanicals repellents resulted no protective. Repellents with DEET provided more
protection against A. aegypti and botanical repellents, including impregnated wristbands pro-
vided no protection [33, 34].
5.4. Larvicide
The selection of the larvicide was supported by previous evaluations of its efficacy under labora-
tory and field conditions and in consistency with the list of available products recommended by
the Mexican Ministry of Health [35–38]. The product selected was the biorational and environ-
mentally friendly larvicide Natular® DT (Spinosad 7.48%; Clarke Mosquito Control, IL, USA;
WHOPES approved) which is available in the formulation of a tablet for containerized water.
This product and formulation is a highly effective larvicide againstA. aegyptiwith a residuality of
9 weeks in field studies. In addition is non-toxic to humans, and also an option for the manage-
ment of insecticide resistance for local A. aegypti populations.
5.5. Aedes aegypti-proof houses
The intervention called Aedes aegypti-proof houses (“Casas a prueba de Aedes aegypti”) involves
insecticide-treated house screening (ITS) with use long-lasting insecticidal nets (LLIN) perma-
nently fitted to windows and doors to exclude A. aegypti, vector of dengue, chikungunya and
Zika (Figure 6).
The selection of these interventions was based on previous studies of our group. Briefly, from
2009 to 2014, cluster randomized controlled trials were conducted in the Mexican cities of
Acapulco and Merida. Intervention clusters received Aedes aegypti-proof houses with ITS and
followed-up during 2 years. Overall, results showed significant and sustained reductions on
adult vector densities in houses in the treated clusters with ITS after 2 years: ca. 50% on the
presence (OR ≤ 0.62, P < 0.05) and abundance (IRR ≤ 0.58, P < 0.05) of indoor-resting adults. ITS
Figure 6. Aedes aegypti-proof houses.
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on doors and windows are ‘user-friendly’ tool, with high levels of acceptance, requiring little
additional work or behavioral change by householders. ITS is a housing improvement that
should be part of the current paradigms for urban vector-borne disease control [36].
As described in Che-Mendoza et al. [37] andManrique-Saide et al. [39], Duranet® screens (0.55%
w.w. alpha-cypermethrin-treated non-flammable polyethylene netting [145 denier; mesh1⁄4132
holes/sq. inch]; Clarke Mosquito Control, Roselle, IL, USA; WHOPES approved for LLIN use)
were mounted in aluminum frames custom-fitted to doors and windows of houses in collabora-
tion with a local small business [37, 40]. An average of two doors and five windows by house
were installed in each intervention cluster. During installation, at least one person in every
household received information from research staff about the proper use andmaintenance of ITS.
5.6. Government agency as key partner in the intervention
These tools and interventions have fully political support by the Government of the State of
Yucatán who also gave financial support. In Merida, a strong collaborative work with local
authorities is already on-going and with this information we are already starting interventions
(and will start others) targeting high-risk areas and vulnerable populations. The authorities of
Mexico are considering how to expand Aedes-proof housing to as many homes as possible,
probably as a targeted intervention for high-risk areas (hot-spots) of endemic localities.
6. Zika, culture and pregnancy: An anthropological overview
The particularity of Zika virus presents a ‘double identity’ because it belongs to mosquito
vector-borne diseases and sexually transmitted infections. The initial cultural meanings of
ZIKV produced in local population uncertainty, misinformation, social fears and rumours.
Even in social networks like Facebook or Twitter, there was an entanglement of discourses that
increased confusion about symptoms, treatments, and consequences of this new outbreak.
Currently, we have noticed that incommensurability continues at stake on the cultural dimen-
sion of this emergent disease. That’s the reason why an anthropological overview will help us
to a better understanding of the sociocultural determinants of ZIKV. The final purpose is to
address cultural barriers and social acceptance of an integrated prevention model that pursuit
improves population health in Yucatan.
6.1. Research process
Our group of anthropologists is currently conducting three studies as part of this integrated
prevention model. First one, there is a research focused on sociocultural factors that pregnant
women associated with Zika virus in Yucatan, Mexico. Ethnographic and in-deep interview
methods are used for the collection data. The guidelines of this study are: source of informa-
tion about ZIKV; the mechanisms associated with Zika infection; social perceptions of symp-
toms; cultural beliefs about microcephaly and Guillain-Barre Syndrome; risk perceptions on
Zika virus; and the prevention and control practices of this target population. Also, we make
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anthropological analysis on focus group and workshops activities developed by medical crew
with pregnant women.
Second, there is research which main goal is focused on human mobility and its relation with
DENV, CHIKV and ZIKV transmission in Yucatan. A former and pioneer study was deployed
in Iquitos, Peru since 2007 [40]. We adapted surveys applied there to Yucatecan context,
coordinated by Gonzalo Vazquez-Prokopec. There are two types of questionnaires: the retro-
spective movement survey and the prospective movement survey. The first one, will help to
identify the amount of time DEN/CHIK/ZIKV-infected person spends at home as well array
locations. The second one is for not infected individuals. In both cases, we want to know about
their routine movements and the time-spatial quantification of them.
Third, we are making a rapid assessment on social perception about insecticide-treated screen-
ing (Aedes aegypti-proof houses). Pregnant women and their families are the main target of this
study. The topics this survey are: acceptance of the intervention, installation process, family
perception on positive and negative impacts of this technological innovation, comfort and heat
perception, families’ opinion on scale-up this project.
Finally, we are conducting a sociological assessment on the integrative prevention model. We
seek to address what is the social perception of pregnant women about the intervention (enroll-
ment process, information of Zika and ABD prevention practices), and follow-up health care of
pregnancy). In addition, we are exploring with in-deep interviews vulnerability experiences that
pregnant women have lived during and after the emergence of Zika outbreak in Yucatan.
6.2. Anthropological contributions
We expect, that this three and incoming social studies, will provide cross-cultural perspectives
on entomological, medical, ecological and epidemiological approaches. The common goal to
achieve, as a multidisciplinary team, is to produce a very positive impact of named interven-
tions in collaboration with local communities and government institutions. Since anthropolog-
ical point of view, we are strengthening the integrated prevention model by studying how
human factor is interweaved in an eco-bio-social context.
7. Discussion and conclusions
Here we described and discussed the design and current implementation of an integrated
model for primary and secondary preventive interventions for ZIKV, along with other ABD
and sexually transmitted infections that impact reproductive health, pregnancy and perinatal
life stages in women and their upspring in Merida, Mexico.
This intervention is being developed in a population of 10,000 people of the city of Merida and
with the participation of a multidisciplinary group of public health professionals (epidemiolo-
gists, obstetricians, geneticists, virologists, immunologists, pathologists, entomologists, ecolo-
gists, sexologists and anthropologists), in collaboration with the Ministry of Health and the
Government of Yucatan.
An Integrated Intervention Model for the Prevention of Zika and Other Aedes-Borne…
http://dx.doi.org/10.5772/intechopen.71504
63
on doors and windows are ‘user-friendly’ tool, with high levels of acceptance, requiring little
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should be part of the current paradigms for urban vector-borne disease control [36].
As described in Che-Mendoza et al. [37] andManrique-Saide et al. [39], Duranet® screens (0.55%
w.w. alpha-cypermethrin-treated non-flammable polyethylene netting [145 denier; mesh1⁄4132
holes/sq. inch]; Clarke Mosquito Control, Roselle, IL, USA; WHOPES approved for LLIN use)
were mounted in aluminum frames custom-fitted to doors and windows of houses in collabora-
tion with a local small business [37, 40]. An average of two doors and five windows by house
were installed in each intervention cluster. During installation, at least one person in every
household received information from research staff about the proper use andmaintenance of ITS.
5.6. Government agency as key partner in the intervention
These tools and interventions have fully political support by the Government of the State of
Yucatán who also gave financial support. In Merida, a strong collaborative work with local
authorities is already on-going and with this information we are already starting interventions
(and will start others) targeting high-risk areas and vulnerable populations. The authorities of
Mexico are considering how to expand Aedes-proof housing to as many homes as possible,
probably as a targeted intervention for high-risk areas (hot-spots) of endemic localities.
6. Zika, culture and pregnancy: An anthropological overview
The particularity of Zika virus presents a ‘double identity’ because it belongs to mosquito
vector-borne diseases and sexually transmitted infections. The initial cultural meanings of
ZIKV produced in local population uncertainty, misinformation, social fears and rumours.
Even in social networks like Facebook or Twitter, there was an entanglement of discourses that
increased confusion about symptoms, treatments, and consequences of this new outbreak.
Currently, we have noticed that incommensurability continues at stake on the cultural dimen-
sion of this emergent disease. That’s the reason why an anthropological overview will help us
to a better understanding of the sociocultural determinants of ZIKV. The final purpose is to
address cultural barriers and social acceptance of an integrated prevention model that pursuit
improves population health in Yucatan.
6.1. Research process
Our group of anthropologists is currently conducting three studies as part of this integrated
prevention model. First one, there is a research focused on sociocultural factors that pregnant
women associated with Zika virus in Yucatan, Mexico. Ethnographic and in-deep interview
methods are used for the collection data. The guidelines of this study are: source of informa-
tion about ZIKV; the mechanisms associated with Zika infection; social perceptions of symp-
toms; cultural beliefs about microcephaly and Guillain-Barre Syndrome; risk perceptions on
Zika virus; and the prevention and control practices of this target population. Also, we make
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anthropological analysis on focus group and workshops activities developed by medical crew
with pregnant women.
Second, there is research which main goal is focused on human mobility and its relation with
DENV, CHIKV and ZIKV transmission in Yucatan. A former and pioneer study was deployed
in Iquitos, Peru since 2007 [40]. We adapted surveys applied there to Yucatecan context,
coordinated by Gonzalo Vazquez-Prokopec. There are two types of questionnaires: the retro-
spective movement survey and the prospective movement survey. The first one, will help to
identify the amount of time DEN/CHIK/ZIKV-infected person spends at home as well array
locations. The second one is for not infected individuals. In both cases, we want to know about
their routine movements and the time-spatial quantification of them.
Third, we are making a rapid assessment on social perception about insecticide-treated screen-
ing (Aedes aegypti-proof houses). Pregnant women and their families are the main target of this
study. The topics this survey are: acceptance of the intervention, installation process, family
perception on positive and negative impacts of this technological innovation, comfort and heat
perception, families’ opinion on scale-up this project.
Finally, we are conducting a sociological assessment on the integrative prevention model. We
seek to address what is the social perception of pregnant women about the intervention (enroll-
ment process, information of Zika and ABD prevention practices), and follow-up health care of
pregnancy). In addition, we are exploring with in-deep interviews vulnerability experiences that
pregnant women have lived during and after the emergence of Zika outbreak in Yucatan.
6.2. Anthropological contributions
We expect, that this three and incoming social studies, will provide cross-cultural perspectives
on entomological, medical, ecological and epidemiological approaches. The common goal to
achieve, as a multidisciplinary team, is to produce a very positive impact of named interven-
tions in collaboration with local communities and government institutions. Since anthropolog-
ical point of view, we are strengthening the integrated prevention model by studying how
human factor is interweaved in an eco-bio-social context.
7. Discussion and conclusions
Here we described and discussed the design and current implementation of an integrated
model for primary and secondary preventive interventions for ZIKV, along with other ABD
and sexually transmitted infections that impact reproductive health, pregnancy and perinatal
life stages in women and their upspring in Merida, Mexico.
This intervention is being developed in a population of 10,000 people of the city of Merida and
with the participation of a multidisciplinary group of public health professionals (epidemiolo-
gists, obstetricians, geneticists, virologists, immunologists, pathologists, entomologists, ecolo-
gists, sexologists and anthropologists), in collaboration with the Ministry of Health and the
Government of Yucatan.
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There is not a full understanding of the risk for pregnant women, and the teratogenicity of
prenatal infections with ZIKV has not been completely elucidated [7, 10, 11, 13–15]. It is urgent
that a protocol designed for surveillance of pregnant women in endemic and invasive zones of
A. aegypti allow collection of information about the effects of ZIK in pregnant women, and to
delineate the neonatal phenotype of congenital abnormalities of the fetus related with ZIK.
This protocol will allow the establishment strategies related to the prevention and control of
emerging infectious diseases for future use [41, 42].
The implementation of complementary, innovative (not included by the traditional vector con-
trol programs), feasible and locally adapted approaches to vector control to reduce the risk of
Zika and other ABD, through personal protection, environmental management and community-
based partnership models can improve the current strategies for ABD prevention and control.
The results from the surveillance in a vulnerable population, will enable at least four strategies: (1)
create a program focused on a rapid recognition of any clinical symptoms for ZIKV; (2) set up
rehabilitation programs for motor, hearing and visual disabilities in order to support
neurodevelopment and quality of life for patients; (3) determine the performance of current vector
control and (4) establish measures and protocols in accordance with each specific population to
ensure the best results in surveillance, prevention and control of vector-borne diseases in vulner-
able populations. Finally, this strategy will allow development of human resources in research,
including educational cooperation and special experience in handling patients affected by ZIKV.
Therefore, this proposal will have direct impact on social, educational, economic and environ-
mental aspects concerned with the general health of the population, the collaboration and
engagement with government institutions are key factors to accomplish common goals on
public health and preventive strategies against vector-borne diseases.
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There is not a full understanding of the risk for pregnant women, and the teratogenicity of
prenatal infections with ZIKV has not been completely elucidated [7, 10, 11, 13–15]. It is urgent
that a protocol designed for surveillance of pregnant women in endemic and invasive zones of
A. aegypti allow collection of information about the effects of ZIK in pregnant women, and to
delineate the neonatal phenotype of congenital abnormalities of the fetus related with ZIK.
This protocol will allow the establishment strategies related to the prevention and control of
emerging infectious diseases for future use [41, 42].
The implementation of complementary, innovative (not included by the traditional vector con-
trol programs), feasible and locally adapted approaches to vector control to reduce the risk of
Zika and other ABD, through personal protection, environmental management and community-
based partnership models can improve the current strategies for ABD prevention and control.
The results from the surveillance in a vulnerable population, will enable at least four strategies: (1)
create a program focused on a rapid recognition of any clinical symptoms for ZIKV; (2) set up
rehabilitation programs for motor, hearing and visual disabilities in order to support
neurodevelopment and quality of life for patients; (3) determine the performance of current vector
control and (4) establish measures and protocols in accordance with each specific population to
ensure the best results in surveillance, prevention and control of vector-borne diseases in vulner-
able populations. Finally, this strategy will allow development of human resources in research,
including educational cooperation and special experience in handling patients affected by ZIKV.
Therefore, this proposal will have direct impact on social, educational, economic and environ-
mental aspects concerned with the general health of the population, the collaboration and
engagement with government institutions are key factors to accomplish common goals on
public health and preventive strategies against vector-borne diseases.
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Abstract
Zika virus, a flavivirus, has arrived to Latin America in 2013. It became evident causing
epidemics since 2015, first in Brazil and later in other countries in the region, such as
Colombia, with a higher peak in 2016. The World Health Organization (WHO), based on
cumulated evidence on its association with Guillain-Barre syndrome (GBS) and micro-
cephaly and other birth defects (also the congenital Zika syndrome, CZS), declared for a
period of almost a year, an international public health emergency. Epidemics in the region
caused around 1 million cases with also additional complications beyond GBS and the
CZS, which in patients with comorbidities lead to deaths. Among the events studied in the
region, a number of cases with arboviral coinfections/codetection (dengue and chikungunya)
were described and published beginning in Colombia and later in Brazil. In addition to
that, cocirculation and still ongoing research on antibody-dependent enhancement (ADE)
are challenges for physicians and public health authorities, given the implications for
clinical manifestations and serological diagnosis in patients with previous exposition to
other flaviviruses. We reviewed such aspects in this chapter.
Keywords: Zika, flavivirus, dengue, chikungunya, coinfection, cocirculation, arboviruses,
epidemics, epidemiology
1. Introduction
Latin America and the Caribbean (LAC) have been threatened by an unprecedented explosion
of emergent and reemerging arboviral epidemic outbreaks, such as the recent Zika virus
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(ZIKV) and chikungunya virus (CHIKV) epidemics, but certainly in addition to previous
endemoepidemic seasons of urban dengue (DENV) and sylvatic yellow fever (YFV). These
emerging viral infections are largely due to a number of factors such as climate change, levels
of urbanization, migration and tourism, commercial exchange activities, susceptible geograph-
ical areas (tropical and subtropical regions), as other, that have provided an ideal blend for
vector availability and virus spreading among susceptible hosts. These have allowed a spill-
over of these pathogens from their naturally occurring niches and reservoirs to susceptible
urban settings and newly unexposed geographic areas, showing how viruses are dynamic
players in the ecology of the planet, particularly in tropical and subtropical areas [1, 2].
Figure 1. Conditions prone for arboviral Aedes vectors proliferation. Area endemic for Zika and other arboviruses
cocirculation and coinfections, La Virginia Risaralda, Colombia.
Current Topics in Zika72
Arboviruses of medical importance (https://www.ncbi.nlm.nih.gov/Taxonomy/) are mostly
included in the families Flaviviridae, Togaviridae, and Bunyaviridae. The Flaviviridae family
includes dengue virus (DENV), yellow fever virus (YFV), Zika virus (ZIKV), and the Japanese
encephalitis virus group (including the Japanese encephalitis virus, JEV, Usutu virus, USUV,
and the West Nile virus WNV) [1–4]. The Togaviridae family includes chikungunya virus
(CHIKV), Eastern equine encephalitis virus (EEEV), Mayaro virus (MAYV), Ross River virus
(RRV), Sindbis virus (SINV), Venezuelan equine encephalitis virus (VEEV), and Western
equine encephalitis virus (WEEV). Oropouche virus (OROV) belongs to the family
Bunyaviridae [2, 3].
ZIKV shares multiple biological clinical similarities with other of those flaviviral and non-
flaviviral arboviruses [1, 2]. The mosquito vectors Aedes aegypti and Ae. albopictus have facili-
tated these viruses’ propagation; and have challenged the existing response capacities of local
health systems. Many of the affected countries in Latin American countries were already
facing existing challenges to build robust and reliable health systems [1, 4]. The presence of
Ae. aegypti and Ae. albopictus is facilitated by socioeconomical and urban ecoepidemiological
conditions, particularly the presence of old tires, where rain water is cumulated in poverty
endemic areas (Figure 1).
In 2015, ZIKV emerged in LAC (although circulated apparently since 2013 in a silent pattern)
as a leading public health priority, approximately 2 years after the CHIKV epidemic, leading to
ZIKV, CHIKV, and DENV cocirculation, and the reporting of coinfections in different combi-
nations. Although in the case of ZIKV infection, 80% of cases could be asymptomatic, clinical
diagnosis of ZIKV, CHIKV, and DENV remains a challenge due to the considerable overlap in
clinical presentations between them, and with other viral and nonviral infections [1, 4, 5], in
addition also the problem of infection in patients with existing comorbidities that can lead to
atypical, severe, and even fatal cases.
2. Cocirculation and coinfection of arboviruses
Currently, one of the major public health and biomedical challenges for the region is
represented by cocirculation and coinfection of different flaviviral and nonflaviviral arbovi-
ruses [1, 5–9]. Their differentiation as their cross-reactivity between flaviviruses, particularly,
implies immunological and diagnostic problems, when used serological tests [10–13].
The cocirculation of ZIKV, CHIKV, and DENV, in addition to other emerging and remerging
pathogens (such as YFV, MAYV, OROV, among others), presents a number of challenges for
clinical care and laboratory diagnosis in endemic areas [1, 13–21].
Patients infected with one ormore of these viruses can present with similar clinical manifestations
over a wide range of viremia, in some cases, suspecting that with coinfections, clinical symptoms
of one of the infections can predominate while the other being asymptomatic [1, 22–24].
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Clinical manifestations can initially guide the differential diagnosis and possibility of coinfec-
tion for the physicians, even in primary care, however, being challenging in multiple cases
given the overlap of multiple symptoms (Table 1) [1].
This should be complemented with the epidemiological information of each case and epide-
miology of cocirculating arboviruses, which is changing but available through multiple sys-
tems (e.g., WHO, Pan-American Health Organization [PAHO], ProMEDmail, RECOLZIKA).
The broad range of possible viral and nonviral coinfecting agents and the nonspecific signs
and symptoms at the initial stages of infection complicate even more the diagnostic approach
to these cases, beyond the clinical aspects, implying as well the needs for the so-called multi-
plex diagnostic tools (specially molecular, those detecting RNA) to confirm a diagnosis of
single infection or coinfection [1, 6, 7]. Recent field and clinical data have indicated that in
nature, the people and mosquitoes may be infected by multiple arboviruses more frequently
than has been previously appreciated, but still epidemiological studies need to approach in
which proportion these occur during epidemics and nonepidemic seasons. In addition, expo-
sure to multiple viruses tended not to affect mosquito susceptibility: mosquito midgut infec-
tion rates for each virus are similar whether the virus was delivered alone or in combination
with another arbovirus [8, 11, 17]. Once a mosquito is infected, the virus disseminates through
the mosquito body and replicates in the salivary gland before reaching the saliva to be trans-
mitted [8]. In addition to this, there is no clear information yet on how is the viral interaction
among infected cells, if they infected different cells, and how the immune cells in the human
host as well in the mosquito interact when coinfections occur [8–15].
Clinical findings Main arboviruses
CHIKV DENV MAYV ZIKV
Fever +++ ++++ ++++ ++/0a
Myalgia/arthralgia ++++ +++ +++ ++
Edema in limbs 0 0 0 ++
Maculopapular rash ++ ++ ++ +++b
Retro-ocular pain + ++ ++ ++
Conjunctivitis, nonpurulent + 0 0 +++
Lymphadenopathies ++ ++ + +
Hepatomegaly ++ 0 + 0
Leukopenia/thrombocytopenia ++ +++ ++ 0/+c
Hemorrhages + +++ 0 0/+c
aDepends on geography and phylogeny of the virus, in some areas, patients do not have fever.
bPruriginous (mild to severe).
cIn some cases, these findings have been reported.
Table 1. Main clinical findings in CHIKV, DENV, MAYV, and ZIKV [1].
Current Topics in Zika74
The ability of Ae. aegypti mosquitoes to be coinfected and cotransmit arboviruses could have
important implications for the epidemiology, epidemics and syndemics (multiple simulta-
neous epidemics). The likelihood of coinfection by multiple Ae. aegypti-borne viruses may be
increasing, especially during syndemics and high attack rates with multiple infected hosts.
The first report of CHIKV and DENV coinfection occurred in 1964; those arboviruses were
isolated from a single blood specimen taken from a patient in the acute phase of a dengue-like
illness seen at Christian Medical College Hospital, Vellore, South India, in October that year
[8]. The first cases of ZIKV coinfection and other arboviruses have already been reported:
with DENV in New Caledonia in 2015 [9], which occurred in a traveler coinfected with ZIKV
and DENV-3 and a local patient who was coinfected with ZIKV and DENV-1. In Colombia,
during the beginning of ZIKVepidemics, a triple coinfection (the first globally reported), with
DENVand CHIKV was reported in 2016 [10]. Also, in Colombia, in a pregnant woman, ZIKV
with DENV and CHIKV was reported in the same year [11], in this case with a positive
evolution.
When symptomatic infection with both ZIKVand DENVoccurs, the clinical manifestations are
apparently more severe [12]. However, it is not clear whether coinfection with multiple viruses
could result in interspecific competition and interference during various stages of infection, or
whether infection with one virus could enhance transmission of another, since our current
understanding of coinfection and cotransmission by Aedes mosquitoes is limited [8].
Symptoms presented in reported cases of coinfections were severe arthralgia and joint swell-
ing, nevertheless, the impact of coinfection of ZIKV and DENV on severity of illness in
patients remains to be determined [12]. Recently, a study in Tolima, Colombia, following
patients with post-CHIKV chronic inflammatory rheumatism (pCHIK-CIR), identified that
in those patients with sequential (posterior) ZIKV infection, frequency of arthralgia and
rheumatological persistent symptoms was higher [13]. The prevalence of arthralgia was
higher in the group with Zika (50%) than the group without Zika post-CHIKV infection
(33%). With further studies, it may be possible to prove if initial CHIKV infection is a risk
factor for Zika virus disease, or if infection by other viruses after CHIKV increases likelihood
of prolonging and/or intensifying the symptoms of the chronic phase. It cannot be ruled out
that there are other cases of double or even triple coinfection (dengue, chikungunya, and
Zika), as has been reported in Colombia in 2016 and it is also a key point to continue
researching [13]. Even more, in such areas, during outbreaks, such as those occurred during
2015 for CHIKV and later for ZIKV in 2016, patients in countries such as Colombia were
tested primarily for DENV, and just when negative tested for CHIKV, and if negative for
DENV and CHIKV, then tested for ZIKV. This was the framework of the arboviruses sentinel
network, which initially not allowed the detection of coinfections. Nevertheless, in the context
of certain cases and research, clinicians were aware of infections with multiple pathogens in
the differential diagnosis of dengue-like illness, especially in patients who returned from
tropical and endemic areas [9–11, 14]. Coinfection diagnostic procedure could be improved
by using multiplex RT-PCR, given the frequent cocirculation of multiple arboviruses in
tropical regions [9–11, 14].
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In Recife, northeast Brazil, the ZIKV and CHIKV coinfection has been associated with a severe
case of meningoencephalitis associated with peripheral polyneuropathy in a 74-year-old
patient [15], and a few cases of exanthematous illness associated with ZIKV, CHIKV, and
DENV [16] also in Salvador, Bahía, Brazil have been reported. Although neurologic distur-
bances associated with several arboviruses were recognized, apparently there is a much higher
frequency in neurological impairment following CHIKV and ZIKV infection than those
resulting from DENV [15]. Nevertheless, as DENV is also neuropathogenic [17], multiple
neurological consequences can occur during coinfections at this level, including central but
also peripheral manifestations, including the Guillain-Barre syndrome, not only reported for
ZIKV [18] but also for DENV [19] and CHIKV [20–22].
Some guidelines in USA and Brazil have been formulated to assist clinicians in assessing ZIKV
in patients with DENV and CHIKV negative samples and in those who are negative on
sequential testing for both pathogens. However, even if these guidelines are followed,
coinfections may be missed [5, 11]. This complicates the diagnosis of patients with an acute
febrile illness, as the spectra of clinical manifestations that result from infection with these
viruses overlap significantly. Diagnosis is further complicated by cross-reactions observed in
ZIKV-positive patients tested using immunoglobulin M (IgM) or nonstructural protein 1 (NS1)
assays for DENV and vice versa and by limited data on the duration of anti-CHIKV immuno-
globulin M positivity following acute infection. Molecular diagnostics can be used to detect
and differentiate ZIKV, CHIKV, and DENV in the acute phase, and real-time reverse-
transcription polymerase chain reaction (rRT-PCR) can provide quantitative data in addition
to qualitative detection [6, 7, 23]. Where, these viruses cocirculate, especially in LAC, multiplex
arbovirus detection including ZIKV, CHIKV, and DENV should be implemented for at-risk
patients, including pregnant women, employing the same recommendations that have been
issued for the screening of blood donors. A commercial multiplex molecular assay detecting
ZIKV, CHIKV, and DENV has recently been accredited by the US Food and Drug Administra-
tion and may be used in routine practice [11]. In addition to these arboviruses, as mentioned,
YFV, MAY, OROVas well different viral encephalitis viruses, should be also considered in this
emerging scenario where is difficult to predict which of them will be the main arbovirus
causing epidemics [24–26]. Given this complex scenario, any in public health and infectious
diseases would be “paranoid” and trying to know who is the next one arbovirus that is
knocking at our house door, wishing to be protected from its arrival, asking ourselves, “who
can it be now?,” as the title and lyrics of Collin Hay, in the 1981 pop song recorded by the
Australian band “Men at Work.” In our case, our fear and related anxiety is based on true facts
that have been demonstrated by recent epidemics. Then and last, we need to increase our
preparedness for emerging zoonotic and nonzoonotic arboviruses, their potential impacts and
particularly to improve the vector control in tropical countries, as those in Latin America [24].
Till today, there are no single recommendations for management and treatment of such
coinfections. Although that, general sense tends to recommend to orient the management to
the control of the more severe of the infecting pathogens, e.g., DENV, but certainly not only
acute, but also chronic implications of such coinfections (such as ZIKV and CHIKV), should be
considered and followed up properly on time in order to mitigate on time their consequences
[13, 27–36].
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Arbovirus coinfections are not the only coinfections reported. In some patients with other
pathologies, an incidental diagnosis of ZIKV has been made. This situation is observed mainly
in some tropical regions, where the requests for laboratory diagnosis of any arboviral infection
(ZIKV, CHIKV, and DENV) in a hospitalized patient are systematically tested, as part of the
public health surveillance scheme. Cocirculation of pathogens that cause acute febrile illness
(AFI) complicates clinical diagnosis of patients, which can result in delays in initiating lifesaving
medical interventions, as a fatal case of leptospirosis and ZIKV coinfection reported in Puerto
Rico, in which ZIKV infection masked leptospirosis [37–39]. About malaria coinfection, it is
described that a malaria infection may interfere with the specificity diagnosis laboratory for
ZIKV, in that way, malaria may have led to false ZIKV-ELISA positives. However, the possibility
of coinfection with malaria in endemic areas should be considered, tested, and treated [40, 41].
The broad symptomatic spectrum of some chronic diseases can mask the presences of other
diseases, including infections. Therefore, it is important to describe the potential role played by
sexually transmitted infections, mainly acute human immunodeficiency (HIV) infections,
which usually debuts like fever and not specific rash which can be caused by a multitude of
other pathogens, such as ZIKV, which can even be transmitted by sexual activity [42–45].
With the human immunodeficiency virus (HIV), there have been concerns about its implica-
tions. As HIV-infected adults with severe immunosuppression (e.g., a low CD4 cell count or an
AIDS defining illness) experience more severe complications with infections in general, close
clinical monitoring of Zika virus infection should be considered in these situations. More
research is needed. Until now, there are only few case reports in the literature, but these have
occurred mainly in patients under antiretroviral therapy (ARV), then with good levels of CD4
[43, 44, 46–52].
Finally, a very recent study in Colombia confirmed that coinfections would occur more than
expected [53], among 157 patients in the Colombian-Venezuelan border, they found 7.6% with
dengue and chikungunya, 6.4% with dengue and ZIKV, 5.1% with chikungunya and ZIKVand
1.9% with dengue, chikungunya, and Zika.
4. Conclusions
Diagnostic and treatment guidelines for those patients with simultaneous viral infections need
to be urgently developed and tested in order to avoid delays in the diagnosis and associated
mortality Rico [39]. The cocirculation of CHIKV, DENV, and ZIKV among existing ecological
niches in LAC is a major public health challenge that requires efforts in understanding the
transmission dynamics, the spectrum of clinical manifestations, health outcomes, and long-
term sequelae of those coinfected with any of these emerging arboviruses [1, 11, 24]. The
incidence and/or prevalence of coinfections is still a matter of concern for clinical reasons, but,
its epidemiological assessment has not been furtherly studied even in the context of recent
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epidemics. Efforts should focus on the necessity to contain the ongoing concurrent and future
epidemics and to maintain strict and continued surveillance programs to monitor the spread of
these viruses as well as the introduction of newly emergent pathogens [1, 8, 11]. In the field as
well as in low-income and remote areas, clinicians should take into consideration the
overlapping clinical features shared among these agents as well as the possibility of coinfection
in their differential diagnosis. Hopefully, clinical tools, such as the use of the term
“ChikDenMaZika syndrome” [1], will provide clinicians with a useful mnemonic tool that
would aid in narrowing-down diagnosis when faced with arboviral-like disease symptoms
such as fever, maculopapular rash, arthralgias, myalgias, and nonpurulent conjunctivitis (or
conjunctival hyperemia). Such multiagent targeted approach in clinical diagnostics should also
be extrapolated to the laboratory bench by improving the usage of multiplex RT-PCR diagnos-
tic platforms for arboviruses in returning travelers, as well as residents of endemic areas, given
the increasing reported frequency of cocirculation of multiple arboviruses and its emerging
threat in tropical regions.
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